New medical treatments
A combination of SULF1, ANG2, and ANG1 inhibitors, particularly anti-SULFl and anti-ANG2 antibodies, promotes angiogenesis in ischemic myocardium, addressing the limitations of existing treatments for myocardial infarction and ischemic heart disease by enhancing blood vessel formation and reducing fibrosis.
Patent Information
- Application Number
- GB2025005326
- Authority / Receiving Office
- GB · GB
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-04-09
- Publication Date
- 2026-11-11
AI Technical Summary
Existing treatments for myocardial infarction and ischemic heart disease are inadequate due to limited understanding of angiogenic regulatory mechanisms in adult cardiac muscle, leading to insufficient angiogenesis and increased risk of heart failure.
A combination therapy using inhibitors of Sulfatase 1 (SULF1) and Angiopoietin-2 (ANG2) with Angiopoietin-1 (ANG1) to promote therapeutic angiogenesis in ischemic myocardium, administered via anti-SULFl and anti-ANG2 antibodies, optionally with ANG1 enhancers like VEGF.
Enhances angiogenesis and reduces fibrosis, improving cardiac function and preventing heart failure following myocardial infarction.
Smart Images

Figure 00000001_0000 
Figure 00000002_0000 
Figure 00000002_0001
Abstract
Description
TECHNICAL FIELD The present invention relates to novel treatments for myocardial infarction and ischemic heart disease. BACKGROUND OF THE INVENTION Myocardial infarction (Ml), more colloquially known as a "heart attack," is caused by decreased or complete cessation of blood flow to a portion of the myocardium. Often, this is caused by blockage in the coronary arteries that supply blood to the heart. Myocardial infarction may be "silent," and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Ischemic heart disease following myocardial infarction is one of the leading causes of death worldwide [3], [4] and requires immediate action. Blood vessels form complex vascular networks that deliver oxygen and nutrients to ensure cell and tissue growth and survival. Many injured tissues can repair themselves by re-vascularisation initiated by an ischemic angiogenic response. However, other tissue, such as adult myocardium, fails to do so. Heart muscle cannot normally regenerate or maintain itself if deprived of blood supply [1]. Angiogenesis, the formation of new blood vessels lined with endothelial cells, plays a vital role in tissue development, specialisation and maintenance under physiological conditions by maintaining vascular stability and optimal blood flow. Angiogenesis is stimulated by a number of growth factors including fibroblast growth factors (FGFs) and particularly vascular endothelial growth factor (VEGF), as well as via TG F|3-signa 11 i ng, but VEGF mediated angiogenesis fails in adult ischemic myocardium [2], VEGF is a key angiogenic growth factor but present understanding of its role in endothelial cell biology is mainly derived from the use of easily available primary human generic endothelial cells like human umbilical vein endothelial cells (HUVECs). By contrast, little is known about the role of VEGF in endothelial cells from other, more specific, tissues such as myocardium. Delivery of a single angiogenic pathway component, such as VEGF, is unlikely to prove adequate to trigger angiogenesis in highly specialised, non-regenerating tissue types like fully differentiated adult cardiac muscle that, unlike skeletal muscle, does not contain any myogenic stem cells. Restoring blood supply in cardiovascular diseases by stimulating angiogenesis remains challenging due to the limited knowledge of angiogenic cell signalling regulation in the relevant tissue types [5], [6], [7], Some tissue type / endothelial cell type differences have been reported [8, 9], albeit not for cardiac or coronary artery endothelial cells. The recovery of cardiac function and the prevention of the transition to heart failure in Ml patients remains unsatisfactory despite the availability of a wide variety of growth factors since this requires understanding of angiogenic regulatory mechanisms
[10] in the relevant tissue and cell types. Consequently, heart failure following myocardial infarction remains a major cause of death and disability worldwide. Thus, there is a need in the art for additional angiogenic treatments of the heart following myocardial infarction. SUMMARY OF THE INVENTION The present invention is based, in part, on the unexpected finding by the inventor that VEGF levels are stimulated by hypoxia / ischemia in coronary artery endothelial cells, and the understanding that therapeutic myocardial angiogenesis does not require further exogenous supply of VEGF. Instead, the inventor has identified that therapeutic angiogenesis depends on the downregulation of a specific VEGF inhibitor, Sulfatase 1 (SULF1). SULF1 expression is also promoted by hypoxia, thus inhibiting VEGF required for initial endothelial cell proliferative phase. The inventor has further identified that a mismatch between VEGF, SULF1 / SULF2, and angiopoietin (ANG1 / ANG2) cell signalling activities upon the onset of ischemia prevents angiogenesis in ischemic myocardium. The inventor has surprisingly found that angiogenesis in partially ischemic myocardium could be reactivated by inhibiting SULF1, which inhibits both VEGF and ANG1; inhibiting ANG2 activity; and the provision of ANG1 that is not induced by hypoxia. SULF2 downregulation may also help by further inhibiting ANG2 and by reducing fibrosis by TGF0 cell signalling. In response to these findings, the inventor has proposed that therapeutic myocardial angiogenesis can be promoted using anti-SULFl and anti-ANG2 antibodies, together with the inclusion of angiogenic ANG1, during an early stage of myocardial infarction. The present invention thus provides the combination of an inhibitor of Sulfatase 1 (SULF1); an inhibitor of Angiopoietin-2 (ANG2); and Angiopoietin-1 (ANG1), for use in treating myocardial infarction in a subject. Since myocardial infarction may be a precursor of ischemic heart disease, the present invention may be considered to be the combination of the SULF1 inhibitor, the ANG2 inhibitor, and the ANG1, for use in treating or preventing ischemic heart disease in a subject following a myocardial infarction. In an embodiment, the inhibitor of SULF1 is an anti-SULFl antibody. In an embodiment, the anti-SULF1 antibody binds to the catalytic domain of SULF1, preferably human SULF1. In an embodiment, the anti-SULFl antibody is raised against a peptide from the catalytic domain, or a polypeptide comprising or consisting of the catalytic domain of SULF1, preferably human SULF1. In another embodiment, the anti-SULFl antibody binds to the hydrophilic domain of SULF1, preferably human SULF1. In an embodiment, the anti-SULFl antibody is raised against a peptide from the hydrophilic domain, or a polypeptide comprising or consisting of the hydrophilic domain of SULF1, preferably human SULF1. In another embodiment, the anti-SULFl antibody binds to a conserved region between the full length SULF1 polypeptide and shortened splice variant polypeptides of SULF1, as described in WO 2009 / 060229 Al. In an embodiment, the anti-SULFl antibody is antibody A, B or C described in WO 2009 / 060229 that bind to the catalytic domain, the hydrophilic domain, or a conserved region of human SULF1, respectively. In some embodiments, the anti-SULFl antibody is CAB13797, AB168616 or STJ115741. In an embodiment, the inhibitor of ANG2 is an anti-ANG2 antibody. In an embodiment, the anti-ANG2 antibody prevents binding of ANG2 to theTIE2 receptor. In an embodiment, the anti-ANG2 antibody prevents ANG2-dependent antagonism of signalling via the TIE2 receptor. In some embodiments, the anti-ANG2 antibody is as described in EP 3932946 Al, or is STJAP00190, A41356, A46642 or A28554. In an embodiment, the ANG1 is a full length ANG1 polypeptide. In an embodiment, the ANG1 is a polypeptide having at least 70% sequence identity to the sequence of the full length ANG1 polypeptide, and having pro-angiogenic properties of ANG1. In an embodiment, the subject is also administered an ANG1 enhancer. In an embodiment the ANG1 enhancer is VEGF. In some embodiments of the invention, the subject is administered an ANG1 enhancer in place of the ANG1. Thus, in some embodiments, the subject is administered VEGF instead of ANG1. Similarly, in some embodiments the pharmaceutical compositions of the invention may comprise VEGF in place of the ANG1. In an embodiment, the combination further comprises an inhibitor of Sulfatase 2 (SULF2). In an embodiment, the inhibitor of SULF2 is an anti-SULF2 antibody. In an embodiment, the inhibitor of SULF2 is an anti-SULF2 antibody such as those disclosed in Zaman et al., (Zaman et al., Histochemistry and Cell Biology, 2015, vol. 145, pages 67-79). In some embodiments, the anti-SULF2 antibody is SC-271772, LS-C745859 or A46555. In an embodiment, the combination is administered to a coronary artery of the subject. In an embodiment, the combination is administered to the site of a blockage within the coronary artery of the subject. In an embodiment, the combination is administered upstream of the site of blockage within the coronary artery. In an embodiment, the site of blockage within the coronary artery is indicated by an angiogram or CT scan. In an embodiment, the combination is administered via a bypass, a catheter (microcatheter, angioplasty catheter), or a stent. In an embodiment, the combination is formulated in the form of a gel. In an embodiment, the combination is administered after the occurrence of the myocardial infarction in the subject. Typically, the combination is administered within 1-3 days of the myocardial infarction. In some embodiments, the combination is administered within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours of the myocardial infarction. In some embodiments, the subject is also administered another treatment of myocardial infarction. In an embodiment, the other myocardial infarction treatment comprises administration of an antithrombic agent, such as aspirin. In an embodiment, the subject is a mammal, preferably a human. In an embodiment, the combination an inhibitor of SULF1, an inhibitor of ANG2, and ANG1 (optionally with an inhibitor of SULF2 and / or an ANG1 enhancer such as VEGF), promotes growth and / or angiogenesis of coronary artery endothelial cells. The present invention thus provides a combination of an inhibitor of SULF1, an inhibitor of ANG2, and ANG1 (optionally with an inhibitor of SULF2 and / or an ANG1 enhancer), for use in promoting angiogenesis of coronary artery endothelial cells ex vivo. The present invention also provides a pharmaceutical composition comprising an inhibitor of SULF1, an inhibitor of ANG2, and ANG1, and a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides a pharmaceutical composition comprising an inhibitor of SULF1, an inhibitor of ANG2, and ANG1, and a pharmaceutically acceptable carrier, diluent or excipient, for use in medicine, i.e., for use as a medicament. In an embodiment, the pharmaceutical compositions further comprise an inhibitor of SULF2. In an embodiment, the pharmaceutical compositions further comprise an enhancer of ANG1. In preferred embodiments, the inhibitor of SULF1 is an anti-SULFl antibody, the inhibitor of ANG2 is an anti-ANG2 antibody, and the inhibitor of SULF2 is an anti-SULF2 antibody. In some preferred embodiments, the pharmaceutical composition is intended for use in a mammal, preferably a human. Thus, in some preferred embodiments, the anti-SULFl antibody is an anti-human SULF1 antibody, the anti-ANG2 antibody is an anti-human ANG2 antibody, the ANG1 is human ANG1, the anti-SULF2 antibody is an anti-human SULF2 antibody, and the ANG1 enhancer is an enhancer of human ANG1. The present invention thus provides a pharmaceutical composition comprising an anti-human SULF1 antibody, an anti-human ANG2 antibody, and a human ANG1 polypeptide, and a pharmaceutically acceptable carrier, diluent or excipient. In an embodiment, the pharmaceutical composition also comprises an anti-human SULF2 antibody. In an embodiment, the pharmaceutical composition also comprises an enhancer of human ANG1. In some embodiments, the pharmaceutical compositions are for use in medicine, i.e., for use as a medicament. In some embodiments, the pharmaceutical compositions are intended and formulated for use in treating myocardial infarction in a subject. In some embodiments, the pharmaceutical compositions are intended and formulated for use in treating or preventing ischemic heart disease in a subject following a myocardial infarction. Other objects, features and advantages of the present invention will become clear from the following description and drawings. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A is an illustration confirming SULF1 and SULF2 expression following transfection in coronary artery endothelial cell. Figures IB and 2C illustrate gene expression levels of various angiogenic molecules in coronary artery endothelial cells following SULF1 and SULF2 over-expression. Figures 2A and 2B illustrate gene expression levels of various angiogenic molecules in coronary artery endothelial cells in response to hypoxia at various time points. Figures 3A and 3B illustrate gene expression levels of various angiogenic molecules in coronary artery endothelial cells in response to assorted treatments. Figure 3C is an illustration confirming SULF1 and SULF2 expression in coronary artery endothelial cells in response to differential cell signalling exposure. Figure 4A illustrates the effect of SULF1 expression on coronary arterial endothelial cell mass / growth during different phases of growth and differentiation or ageing to highlight the requirement of transient short term Sulfl inhibition. Figure 5B illustrates the effect of SULF1 expression on cell migration during different stages of cellular maturity / ageing of coronary arterial endothelial cells. DETAILED DESCRIPTIONOF THE INVENTION The aim of this invention was to determine why VEGF delivery to adult ischemic myocardium fails to trigger angiogenesis following myocardial infarction, and thereby to provide an improved treatment of myocardial infarction and ischemic heart disease. The inventor has investigated the molecular responses of primary coronary artery endothelial cells and aortic endothelial cells to chemical hypoxia when compared with their responses under normal conditions, as well as the nature of their responses when the levels of some angiogenic factors has changed. Human coronary artery endothelial cells express some VEGF and barely detectable levels of SULF1 or SULF2. SULF1 over-expression in these cells inhibits VEGF and inhibits ANG1, an angiogenic enhancer, but does not inhibit ANG2, an angiogenic inhibitor. SULF2 over-expression generally maintains lower levels of VEGF and TGF0 signalling components but promotes expression of ANG2, the angiogenic inhibitor. SULF1 and SULF2 thus differentially modulate VEGF and VEGF associated cell signalling components, like ANG1 and ANG2, and some TGF0 cell signalling components relevant to angiogenesis and fibrosis. This is further confirmed by chemical hypoxia of coronary artery endothelial cells that upregulates VEGF, SULF1, SULF2 and ANG2 but not ANG1, in addition to increased SMAD2, TGF0, TG F|3 RI I and SMAD5 but not SMAD1. SULF2 only slightly reduces VEGF but markedly promotes ANG2 (Angiopoietin 2) to inhibit angiogenesis. It was concluded that VEGF and ANG1 inhibition by SULF1, and ANG2 promotion by SULF2, together prevent VEGF induced angiogenesis in ischemic myocardium. SULF2 also modulates TGF0 cell signalling to promote fibrosis. Aortic endothelial cells (data not shown) were, in contrast, relatively unresponsive to SULF1 or SULF2 overexpression in their VEGF orTGFP cell signalling responses, showing that the responses described herein are specific to coronary artery endothelial cells and not widespread to endothelial cells in general or present in all arterial endothelial cells. Since hypoxia / ischemia inhibits ANG1, but promotes VEGF, SULF1 / SULF2 and ANG2, in coronary artery endothelial cells, therapeutic myocardial angiogenesis could be promoted using SULF1 and ANG2 neutralising antibodies with inclusion of ANG1, optionally together with SULF2 neutralising antibodies and further optionally with an ANG1 enhancer. The inventor has identified that a combination of factors useful in the treatment of myocardial infarction requires compounds that would inhibit SULF1 to maintain VEGF activity; inhibit ANG2 to moderate the level of SULF2 activity that is promoted by hypoxia to further preserve the VEGF activity; and provide ANG1 activity that is inhibited by hypoxia in coronary artery endothelial cell. Further reducing SULF2 activity moderating TGF0 cell signalling could also limit fibrosis
[12]
[13] and promote cardiomyocyte cell survival. The present invention thus provides the combination of an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1), for use in treating myocardial infarction in a subject. By treating myocardial infarction, we include the meaning that ischemic heart disease is treated or prevented in a subject following a myocardial infarction. Thus, the present invention may also be considered to be the combination of the SULF1 inhibitor, the ANG2 inhibitor, and the ANG1, for use in treating or preventing ischemic heart disease in a subject following a myocardial infarction. The invention further provides a method of treating myocardial infarction in a subject in need thereof, the method comprising administering to the subject a combination of an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1). The invention further provides a method of treating or preventing ischemic heart disease in a subject following a myocardial infarction, the method comprising administering to the subject a combination of an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1). In some preferred embodiments, the inhibitor of SULF1 is an anti-SULFl antibody, and the inhibitor of ANG2 is an anti-ANG2 antibody. Thus, the present invention provides the combination of an anti-SULFl antibody, an anti-ANG2 antibody, and Angiopoietin-1 (ANG1), for use in treating myocardial infarction in a subject. The invention further provides a method of treating myocardial infarction in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a combination of an anti-SULFl antibody, an anti-ANG2 antibody, and Angiopoietin-1 (ANG1). The term "combination" refers to the use of an inhibitor of SULF1 (which may be an anti-SULFl antibody), an inhibitor of ANG2 (which may be an anti-ANG2 antibody), and ANG1 in combination to achieve the treatment of myocardial infarction in a subject. In one embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are formulated together and are administered as a single formulation. In another embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are prepared and administered as two or more separate formulations. In an embodiment, the inhibitor of SULF1 and the inhibitor of ANG2 are formulated and administered together, and the ANG1 is formulated and administered separately. In an embodiment, the inhibitor of SULF1 and the ANG1 are formulated and administered together and the inhibitor of ANG2 is formulated and administered separately. In an embodiment, the inhibitor of ANG2 and the ANG1 are formulated and administered together and the inhibitor of SULF1 is formulated and administered separately. In an embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are each formulated and administered separately. They may be administered concurrently or sequentially. Thus, in some embodiments, the inhibitor of SULF1 (which may be an anti-SULFl antibody), the inhibitor of ANG2 (which may be an anti-ANG2 antibody), and the ANG1 do not need to be administered at the same time, or by the same route of administration, or in the same formulation. Each component of the combination may have a different dosing schedule. In some embodiments, the dosing schedules are temporally overlapping; in some embodiments, one is started before the others; in some embodiments, one ends before the others; in some embodiments, the course of therapy of one agent ends before another begins. In one embodiment, the inhibitor of SULF1 (which may be an anti-SULFl antibody) is administered prior to administration of the inhibitor of ANG2 and the ANG1. In one embodiment, the inhibitor of ANG2 (which may be an anti-ANG2 antibody) is administered prior to administration of the inhibitor of SULF1 and the ANG1. In one embodiment, the ANG1 is administered prior to administration of the inhibitor of SULF1 and the inhibitor of ANG2. In one embodiment, the inhibitor of SULF1 (which may be an anti-SULFl antibody), the inhibitor of ANG2 (which may be an anti-ANG2 antibody), and the ANG1 are administered within about 120 minutes of each other. In one embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are administered within about 60 minutes of each other. In one embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are administered within about 30 minutes of each other. In one embodiment, the inhibitor of SULF1, the inhibitor of ANG2, and the ANG1 are administered essentially concurrently, i.e., within about 15 minutes of each other. In a preferred embodiment the subject is a human and the SULF1 inhibitor (which may be an anti-SULFl antibody) is an inhibitor of human SULF1, the inhibitor of ANG2 (which may be an anti-ANG2 antibody) is an inhibitor of human ANG2, and the ANG1 is a human ANG1 polypeptide or mimic thereof. Sulfatase 1 (SULF1; EC:3.1.6.14) is an extracellular heparan sulfate endosulfatase. The enzyme is secreted through the Golgi and is subsequently localised to the cell surface and selectively removes 6-O-sulfate groups from heparan sulfate chains of heparan sulfate proteoglycans. It has been shown to modulate the activities of many growth factors and signalling molecules by regulating the sulfation status of specific HSPGs (Dhoot GK et al., 2001, "Regulation of Wnt Signaling and Embryo Patterning by an Extracellular Sulfatase". Science 2001, Vol 293, Issue 5535, pp. 1663-1666, DOI: 10.1126 / science.293.5535.1663). It is also described in WO 2009 / 060229 by the present inventor. Human SULF1 is an 871 amino acid polypeptide whose canonical sequence, as well as variants and isoforms, is given in UniProtKB accession number Q8IWU6. Sulfatase 2 (SULF2; EC:3.1.6.1) is another member of the sulfatase enzyme family. It also acts on heparan sulfate proteoglycans (HSPGs), specifically removing the 6-O-sulfate group, which plays a critical role in regulating the release of growth factors and cytokines. SULF2 has been reported to be involved in various biological processes, including cancer progression, and its abnormal expression can lead to structural changes in proteoglycans, resulting in uncontrolled proliferation, increased invasion, and lymphatic metastasis (Huang etal.,Ann. Transl. Med. 2021, vol. 9, page 1439; doi.: 10.21037 / atm-21-4102). It is also described in WO 2009 / 060229 by the present inventor. Human SULF2 is an 870 amino acid polypeptide whose canonical sequence, as well as variants and isoforms, is given in UniProtKB accession number Q8IWU5. SULF1 and SULF2 enzymes do not have identical expression patterns either in development or in adult tissues, and do not have identical biological roles. The angiopoietins are a family of growth factors that are important for vascular development and angiogenesis and have four members - ANG1, ANG2, ANG3 and ANG4 - as well as two related receptors, TIE1 and TIE2. ANG1 and ANG2 have been considered to have complementary functions in maintaining vascular function and integrity in vivo (Hu etal., Curr. Oncol. Rep., 2009, vol. 11, no. 2, 111-116, doi.: 10.1007 / sll912-009-0017-3), but the present invention demonstrates that this is not always the case. Angiopoietin 1 (ANG1; also known as ANG-1, ANGPT1 and KIAA0003) is a growth factor that modulates vascular development, stabilisation and protection by binding to the Tie2 receptor promoting endothelial cell survival and inhibiting vascular leakage (Cho et al., PNAS, 2004, vol. 101, no. 15, 5547-5552). In preclinical studies, it was found that ANG1 may be therapeutically useful in a number of situations, including treatment of edema, endotoxemia, and transplant arteriosclerosis. Further, ANG1 has also been implicated in vessel remodeling, the induction of angiogenesis and pulmonary hypertension (Brindle etal., Circ. Res. 2006, vol. 98, no. 8, 1014-1023, doi.: 10.1161 / 01.RES.0000218275.54089.12). Human ANG1 is a 498 amino acid polypeptide whose canonical sequence, as well as variants and isoforms, is given in UniProtKB accession number Q15389. Angiopoietin 2 (ANG2; also known as ANGPT2) is a protein that acts as an antagonist or nonsignal transducing ligand of the Angiopoietin-1 / Tie2 pathway. ANG2 is a key regulator of angiogenesis, the formation of new blood vessels, and vascular remodeling, the process by which blood vessels are modified. For example, interactions of angiopoietins with the Tie-2 receptor regulate vascular maturation and vessel quiescence (Hegen et al., Arterioslerosis, Thrombosisand Vascular Biology, 2004, vol. 24, no. 10, pages 1803-1809, doi.: 10.1161 / 01.ATV.0000140819.81839). Angiogenesis regulated by ANG2 proceeds through sprouting, endothelial cell migration, proliferation, and vessel destabilisation and stabilisation. Human ANG2 is a 496 amino acid polypeptide whose canonical sequence, as well as variants and isoforms, is given in UniProtKB accession number 015123. In an embodiment, the inhibitor of SULF1 is an anti-SULFl antibody. In an embodiment, the inhibitor of SULF1 (which may be an anti-SULFl antibody) reduces the sulfatase activity of SULF1 by at least 50%. Preferably, the inhibitor of SULF1 reduces the sulfatase activity of SULF1 by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or by at least 99%. In an embodiment, the inhibitor of SULF1 reduces the sulfatase activity of SULF1 to less than 10%, less than 5%, less than 1%, less than 0.5%, less than 0.1% or less than 0.01% of the native sulfatase activity of SULF1. The inhibitor of SULF1 may reduce the sulfatase activity of SULF1 to an undetectable level. Thus, in an embodiment, the anti-SULFl antibody is a SULF1 neutralising antibody, that reduces the sulfatase activity of SULF1 by at least 50% as discussed above. The effect of the SULF1 inhibitor on the sulfatase activity of SULF1 can be assayed by measuring the effect of the inhibitor on the 6-0 sulfation states of HSPGs as described by Ai et al. (2003) and Morimoto-Tomita et al. (2002). For example, one method involves investigating the enzymatic activity of SULF1 on sulphated glycosaminoglycan (GAG) substrates (Ai et al. 2003) in the presence and absence of the inhibitor. As described by Gill etal., 2010
[14] , the neutralisation of SULF1A by Sulfl antibodies may be confirmed by increased sulfation levels of antibody-treated satellite cells observed using immunocytochemical staining with antibody 10E4 that stains heparan sulfate (HS), but not HS following desulfation and removal of this epitope. In an embodiment, the inhibitor of SULF1 reduces SULF1 levels in coronary artery endothelial cell cultures as detected using RT PCR and / or immunostaining methods. Since the application of VEGF cannot normally induce angiogenesis in ischemic myocardium due to inhibition by SULF1, the effect of SULF1 neutralisation should be evident in the appearance of new blood vessel formation at very early stages. For example, myocardial revascularisation may be observed by producing MRI scans of the heart. In some embodiments, the inhibitor of SULF1 is an anti-SULFl antibody. In an embodiment, the anti-SULFl antibody binds to the catalytic domain of SULF1, preferably human SULF1. The catalytic domain of human SULF1 extends from residues 42 to 414. In an embodiment, the anti-SULFl antibody is raised against a peptide from the catalytic domain, or a polypeptide comprising or consisting of the catalytic domain of SULF1, preferably human SULF1. In an embodiment, the anti-SULFl antibody binds to an epitope of human SULF1 that comprises the conserved cysteine residue at position C89 that undergoes post-translational modification to N-formylglycine to form a catalytically active enzyme for sulphate hydrolysis. Mutation of C89 (or both C88 and C89) that disrupts essential N-formylglycine modification in the catalytic site, blocks SULF1 function as demonstrated by the failure of mutated SULF1 to enhance Wnt signalling (as explained in WO 2009 / 060229). In another embodiment, the anti-SULFl antibody binds to the hydrophilic domain of SULF1, preferably human SULF1. As described in WO 2009 / 060229, the hydrophilic domain of human SULF1 extends from residues 416 to 7421. In an embodiment, the anti-SULFl antibody is raised against a peptide from the hydrophilic domain, or a polypeptide comprising or consisting of the hydrophilic domain of SULF1, preferably human SULF1. In another embodiment, the anti-SULFl antibody binds to a conserved region between the full length SULF1 polypeptide and shortened splice variant polypeptides of SULF1, as described in WO 2009 / 060229. In an embodiment, the anti-SULFl antibody is raised against a peptide from a conserved region between the full length SULF1 polypeptide and shortened splice variant polypeptides of SULF1. In an embodiment, the anti-SULFl antibody is antibody A described in WO 2009 / 060229 that binds to the catalytic domain of human SULF1. In an embodiment, the anti-SULFl antibody is antibody B described in WO 2009 / 060229 that binds to the hydrophilic domain of human SULF1. In an embodiment, the anti-SULFl antibody is antibody C described in WO 2009 / 060229 that binds to a conserved regions domain of human SULF1. In some embodiments, the anti-SULFl antibody is CAB13797, AB168616 or STJ115741. CAB13797 is a rabbit anti-Sulfl polyclonal antibody that is commercially available from Thomas Scientific (cat. no.: CHM07U950; URL: https: / / www.thomassci.eom / p / sulfl-rabbit-polyclona!-antibody-20ul?srsltid=AfmBOoqfacJD9YV0zblFmVRlLc4wp0mSZX347dKjhJ8KB27FxHsmnr4d) or Biomol GmbH (cat. no.: G-CAB13797.20; https: / / www.biomol.com / products / antibodies / primary-antibodies / general / anti-sulfl-g-cabl3797.20), and has reactivity against human and rat samples. AB168616 is a mouse polyclonal anti-Sulfl antibody that reacts with human samples suitable for Western Blood (WB). It is commercially available from Labome (cat. no.: PA5-50890; URL: https: / / www.labome.com / product / lnvitrogen / PA5-50890.html), Fisher Scientific (cat. no.: 16264536; https: / / www.fishersci.co.uk / shop / products / 50ug-mouse-polyclonal-sulfatase-1 / 16264536) or Abeam (cat. no.: abl68616; https: / / www.abcam.com / en-us / products / primary-antibodies / sulfatase-l-sulfl-antibody-abl68616?srsltid=AfmBOoqJQ5My5wxogN8y0ihXLglHYxAQmSPytrYpS8Vvg8SJPzgSAaO9#). STJ115741 is a rabbit polyclonal, unconjugated antibody of isotype IgG, with reactivity against human and rats, and is commercially available from St John's Laboratory (cat. no.: STJ115741; https: / / stjohnslabs.com / anti-sulfl-antibody-480-610-stjll5741 / ?srsltid=AfmBOorCC-tgl3aEO5iuWlcFG8isjKV8KX5sm3_DDLrlVWJIXDwbn3Qa) or Sapphire Bioscience (cat. no.: STJ115741; https: / / www.sapphirebioscience.com / product / NS02473388 / anti-sulfl-antibody-(480-610)). In some embodiments, an anti-SULFl monoclonal antibody can be synthesised using procedures described by Gill etal. [26, 27], An anti-SULFl monoclonal antibody can also be synthesised using procedures known in the art and described herein. In some embodiments, since human coronary endothelial cells only express a full length SULF1, the inhibitor of SULF1 may be a shorter inactive splice variant of SULF1 lacking sulfatase activity that blocks SULF1 activity by its dominant-negative activity, such as those disclosed in WO 2009 / 060229 and in Sahota et al. (Sahota AP, Dhoot GK, 2009 "A novel SULF1 splice variant inhibits Wnt signalling but enhances angiogenesis by opposing SULF1 activity." Exp Cell Res. 2009-10; 315(16):2725-64). In some embodiments, the inhibitor of SULF1 may be an antisense oligonucleotide targeting SULF1 RNA transcripts (Dhoot GK et al, 2001). In a preferred embodiment, the inhibitor of ANG2 is an anti-ANG2 antibody. In some embodiments, the anti-ANG2 antibody is an ANG2 neutralising antibody. ANG2 is a ligand forTIE2 that can act as a TIE2 antagonist. In the absence of VEGF, ANG2 can lead to endothelial cell death and blood vessel regression. ANG2, a naturally occurring antagonist, may support growth or regression depending in the presence of other growth factors such as VEGF. ANG2 activity can be determined by identifying the emergence of new blood vessel formation which can be monitored by analysis of the blood flow or histological investigation. In some embodiments, the anti-ANG2 antibody prevents or reduces binding of ANG2 to the TIE2 receptor. In an embodiment, the anti-ANG2 antibody prevents or reduces ANG2-dependent antagonism of signalling via the TIE2 receptor. In some embodiments, the anti-ANG2 antibody restores VEGF levels in coronary artery endothelial cell cultures as determined by RT-PCR and / or immunochemical procedures. In some embodiments, the anti-ANG2 antibody also restores ANG1 levels in coronary artery endothelial cell cultures as determined by RT-PCR and / or immunochemical procedures. In some embodiments, the anti-ANG2 antibody, when administered to a subject following Ml, prevents loss of myocardial troponin I or troponin T proteins in blood. In some embodiments, the anti-ANG2 antibody is as described in EP 3932946 Al, or is STJAP00190, A41356, A46642 or A28554, or may be made using procedures known in the art and described herein. STJAP00190 is an unconjugated mouse monoclonal antibody with human reactivity that is commercially available from St John's Laboratory (cat. no.: STJAP00190; https: / / stjohnslabs.com / human-ang2-angiopoietin-2-antibody-pair-stjap00190 / ?srsltid=AfmBOopLjU08NRg-yUBJkRUJ8Ubcz_rukvjMpDMCatwp-Wc_id3ZKho). A41356 is an unconjugated rabbit polyclonal anti-Ang2 antibody that is commercially available from antibodies.com (cat. no.: A41356; https: / / www.antibodies.com / catalog / primary-antibodies / angiopoietin-2-antibody-a41356). A46642 and A28554 are unconjugated rabbit polyclonal anti-Ang2 antibodies that show reactivity against human, mouse and rat, and are commercially available from antibodies.com (A46642: cat. no.: A46642; https: / / www.antibodies.com / catalog / primary- antibodies / angiopoietin-2-antibody-a46642; A28554: cat. no.: A28554; https: / / www.antibodies.com / catalog / primary-antibodies / angpt2-antibody-a28554). The term "antibody" describes polypeptides comprising at least one antibody-derived antigen binding site ( e.g., VH / VL region or Fv, or CDR). The antibodies may include a single chain or a double chain. An antibody for use in the present invention may be a monoclonal antibody, a bispecific antibody, a human antibody, a humanised antibody, a chimeric antibody, a single-chain Fvs (scFV) fragment, a single-chain antibody, a Fab fragment, a F(ab') fragment, a disulfide-bond Fvs (sdFV) fragment, an anti-idiotype (anti-Id) antibody, an SMIP, anAffibody®, nanobody, a domain antibody, or an epitope-binding fragments of these antibodies, but the present disclosure is not limited thereto. Functionally, the binding affinity of the antibodies to the target molecule may be in the range of 10-5 M to 10 12 M. For example, the binding affinity of the antibodies ranges from 10-6 M to 1012 M, 10’7 M to 1012 M, 10’8 M to 1012 M, 10’9 M to 1012 M, 10’5 M to 1011 M, 10’6 M to 1011 M, 10’7 M to 1011 M, 10’8 M to 1011 M, 10’9 M to 1011 M, 1010 M to 1011 M, 10’5 M to 1010 M, 10’6 M to 1010 M, 10’7 M to 1010 M, 10’8 M to 1010 M, 10’9 M to 1010 M, 10’5 M to 10’9 M, 10’6 M to 10’9 M, 10’7 M to 10’9 M, 10’8 M to 10’9 M, 10’5 M to 10’8 M, 10’6 M to 10’8 M, 10’7 M to 10’8 M, 10’5 M to 10’7 M, 10’6 M to 10’7 M, or 10’5 M to 10’6 M. The antibody also can be of any of the following isotypes: IgGl, lgG2, lgG3, lgG4, IgM, IgAl, lgA2, IgD, and IgE. The antibody may be a naturally occurring antibody or may be an antibody that has been altered (e.g., by mutation, deletion, substitution, conjugation to a non-antibody moiety). For example, an antibody may include one or more variant amino acids (compared to a naturally occurring antibody) which changes a property (e.g., a functional property) of the antibody. For example, numerous such alterations are known in the art which affect, e.g., half-life, effector function, and / or immune responses to the antibody in a patient. The term antibody also includes artificial polypeptide constructs which comprise at least one antibody-derived antigen binding site. The antibody may be an isolated antibody. An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds specifically to SULF1, ANG2 or SULF2 is substantially free of antibodies that bind specifically to antigens other than SULF1, ANG2 or SULF2, respectively). An isolated antibody that binds specifically to SULF1, ANG2 or SULF2 can, however, have cross-reactivity to other antigens, such as SULF1, ANG2 or SULF2 from different species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals. The term "monoclonal antibody" ("mAb") refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., antibody molecules whose primary sequences are essentially identical, and which exhibits a single binding specificity and affinity for a particular epitope. A monoclonal antibody is an example of an isolated antibody. MAbs may be produced by hybridoma, recombinant, transgenic or other techniques known to those skilled in the art. A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies of the invention can include amino acid residues not encoded by human germline immunoglobulin sequences ( e.g., mutations introduced by random or site- specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibodies and "fully human" antibodies are used synonymously. A "humanised antibody" refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins. In one embodiment of a humanised form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen. A "humanised" antibody retains an antigenic specificity similar to that of the original antibody. A "chimeric antibody" refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species, such as an antibody in which the variable regions are derived from a mouse antibody and the constant regions are derived from a human antibody. An "antigen-binding portion" of an antibody (also called an "antigen-binding fragment") refers to one or more fragments of an antibody that retain the ability to bind specifically to the antigen bound by the whole antibody. Thus, the present invention provides the combination of an anti-SULFl antibody, an anti-ANG2 antibody, and ANG1, for use in treating myocardial infarction in a subject. The invention further provides a method of treating myocardial infarction in a subject in need thereof, the method comprising administering to the subject a combination of an anti-SULFl antibody, an anti-ANG2 antibody, and ANG1. By "ANG1" is meant an ANG1 polypeptide or a mimic thereof that acts as ligand for receptor TIE2 and has the angiogenic properties of the full length ANG1 polypeptide acting via the TIE2 receptor. In an embodiment, ANG1 is a polypeptide having at least 70% sequence identity to the sequence of the full length ANG1 polypeptide, and having pro-angiogenic properties of ANG1. In an embodiment, the ANG1 is a polypeptide having at least 80%, at least 90%, or at least 95% sequence identity to the sequence of the full length ANG1 polypeptide, and having pro-angiogenic properties of ANG1. In an embodiment, the ANG1 polypeptide or ANG1 mimic stimulates angiogenesis by at least 50% of the level of full length ANG1 polypeptide. Preferably, the ANG1 polypeptide or ANG1 mimic stimulates angiogenesis by at least 60%, at least 70%, at least 80%, or at least 90% of the level of full length ANG1 polypeptide. In an embodiment, the ANG1 polypeptide or ANG1 mimic stimulates angiogenesis by at least 100%, or more, for example 1.5x, 2x, 3x, 5x or lOx of the level of full length ANG1 polypeptide. Methods for determining the effect of a molecule on angiogenesis are known in the art. For example, compounds can be tested on coronary endothelial cell cultures (that are commercially available) and tested for effects relevant to angiogenesis, such as cell growth / cell proliferation, differentiation etc. The ANG1 polypeptide may encompass peptide homologs containing non-natural amino acid derivatives or non-protein side chains, or peptide salts, or derivatives. The peptide homologs may be used having a terminal carboxy acid, as a carboxy amide, as a reduced terminal alcohol or as any pharmaceutically acceptable salt, e.g., as metal salt, including sodium, potassium, lithium or calcium salt, or as a salt with an organic base, or as a salt with a mineral acid, including sulfuric acid, hydrochloric acid or phosphoric acid, or with an organic acid e.g., acetic acid or maleic acid. Generally, any pharmaceutically acceptable salt of peptides may be used, as long as its biological activities are maintained. The amino acid residues are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the peptide substantially retains the desired functional property. Chemical derivatives may have one or more residues chemically derivatized by reaction of side chains or functional groups. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides, which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acid residues. For example: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted or serine; and ornithine may be substituted for lysine. In addition, a derivative can differ from the natural sequence of the polypeptides by chemical modifications including, but are not limited to, terminal-NHz acylation, acetylation, orthioglycolic acid amidation, and by terminal-carboxlyamidation, e.g., with ammonia, methylamine, and the like. In an embodiment, the subject is also administered an ANG1 enhancer. Figure 3 shows that VEGF promotes the expression of ANG1. Thus, in an embodiment the ANG1 enhancer is VEGF. In an embodiment, the presence of the ANG1 enhancer stimulates angiogenesis by at least 1.5x, 2x, 3x, 5x or lOx compared to the level in the absence of the enhancer. Methods for determining the effect of a molecule on angiogenesis are known in the art. In some embodiments of the invention, the subject is administered an ANG1 enhancer in place of the ANG1. Thus, in some embodiments, the subject is administered VEGF instead of ANG1. Similarly, in some embodiments, the pharmaceutical compositions of the invention may comprise VEGF in place of the ANG1. In some embodiments, the combination further comprises an inhibitor of SULF2. In an embodiment, the inhibitor of SULF2 is an anti-SULF2 antibody. In some embodiments, an anti-SULF2 monoclonal antibody can be synthesised using procedures described by Gill etal. [26, 27], The anti-SULF2 antibody may be selected from: SC-271772, LS-C745859 or A46555, or may be made as described herein. In an embodiment, the inhibitor of SULF2 (which may be an anti-SULF2 antibody) reduces the sulfatase activity of SULF2 by at least 50%. Preferably, the inhibitor of SULF2 reduces the sulfatase activity of SULF2 by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or by at least 99%. In an embodiment, the inhibitor of SULF2 reduces the sulfatase activity of SULF2 to less than 10%, less than 5%, less than 1%, less than 0.5%, less than 0.1% or less than 0.01% of the native sulfatase activity of SULF2. The inhibitor of SULF2 may reduce the sulfatase activity of SULF2 to an undetectable level. Thus, in an embodiment, the anti-SULF2 antibody is a SULF2 neutralising antibody, that reduces the sulfatase activity of SULF2 by at least 50% as discussed above. The effect of the SULF2 inhibitor on the sulfatase activity of SULF2 can be assayed by measuring the effect of the inhibitor on the 6-0 sulfation states of HSPGs as described for SULF1 by Ai et al. (2003) and Morimoto-Tomita et al. (2002). For example, one method involves investigating the enzymatic activity of SULF2 on sulphated glycosaminoglycan (GAG) substrates in the presence and absence of the inhibitor. SC-271772 is a mouse monoclonal IgGi anti-Sulf2 antibody commercially available from Santa Cruz Biotechnology Inc. (cat. no.: sc-271772; https: / / www.scbt.com / p / sulf-2-antibody-g-4?srsltid=AfmBOooRiLYlfYO-v6PYCHiR6ixqJNbPyzSclZbihOK9MgjiK_wul8Ne) or Insight Biotechnology (cat. no.: sc-271772-FITC; https: / / insightbio.com / productinfo / sc-271772-FITC / Santa%20Cruz%20Biotechnology), with reactivity against mouse, rat and human. LS-C745859 is commercially available from LS Bio (cat. no.: LS-C745859; https: / / www.lsbio.eom / targets / target / gl30605#divAntibodyResults). It is of sandwich type and useful for the detection of Sulf-2 of human origin. A46555 is an unconjugated rabbit polyclonal anti-Sulf2 antibody that was raised to a synthetic peptide of human Sulf2, and which is commercially available from antibodies.com (cat. no.: A46555; https: / / www.antibodies.com / catalog / primary-antibodies / sulf2-antibody-a46555). Thus, the present invention provides the combination of an anti-SULFl antibody, an anti-ANG2 antibody, ANG1, and an anti-SULF2 antibody, for use in treating myocardial infarction in a subject. The invention further provides a method of treating myocardial infarction in a subject in need thereof, the method comprising administering to the subject a combination of an anti-SULFl antibody, an anti-ANG2 antibody, ANG1, and an anti-SULF2 antibody. The production of antibodies commonly includes the steps of immunogen preparation, immunisation, antibody isolation and purification. Antibodies and antigen-binding fragments thereof that specifically bind to human SULF1, ANG2, and / or SULF2 can be produced by any method known in the art for the synthesis of antibodies and antigen binding fragments, for example, by chemical synthesis or by recombinant expression techniques. The methods described herein employ, unless otherwise indicated, conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridisation, and related fields within the skill of the art. The antibody, or an antigen-binding fragment thereof, may be produced by culturing a cell or host cell (e.g., a cell or a host cell comprising polynucleotides encoding an antibody or antigenbinding fragment thereof). Typically, the antibody or antigen binding fragment thereof is expressed in a cell or host cell comprising polynucleotides encoding the antibody or antigenbinding fragment thereof. The encoding polynucleotides may have been introduced into the cell. Usually, the antibody or antigen-binding fragment expressed by the cell or host cell is purified. Monoclonal antibodies or antigen-binding fragments thereof can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, yeast-based presentation technologies, or a combination thereof. For example, monoclonal antibodies or antigen-binding fragments thereof can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow E &Lane D, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling GJ et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563 681 (Elsevier, N.Y., 1981), or as described in Kohler G &Milstein C (1975) Nature 256: 495. Examples of yeast-based presentation methods that can be employed to select and generate the antibodies described herein include those disclosed in, for example, WO 2009 / 036379A2; WO 2010 / 105256; and WO 2012 / 009568. In some embodiments, a monoclonal antibody or antigen-binding fragment is an antibody or antigen-binding fragment produced by a clonal cell (e.g., hybridoma or host cell producing a recombinant antibody or antigen-binding fragment), wherein the antibody or antigen binding fragment specifically binds to human SULF1, ANG2, and / or SULF2 as determined, e.g., by ELISA or other antigen-binding assays known in the art. In some embodiments, a monoclonal antibody or antigen-binding fragment thereof can be a chimeric or a humanised antibody or antigenbinding fragment thereof. In some embodiments, a monoclonal antibody or antigen-binding fragment thereof can bea Fab fragment or a F(ab')2 fragment. Monoclonal antibodies or antigenbinding fragments thereof described herein can, for example, be made by the hybridoma method as described in Kohler G &Milstein C (1975) Nature 256: 495 or can, e.g., be isolated from phage libraries using the techniques as described herein. Other methods for the preparation of clonal cell lines and of monoclonal antibodies and antigen-bindingfragments thereof expressed thereby are well known in the art (see, for example, Chapter 11 in: Short Protocols in Molecular Biology, (2002) 5th Ed., Ausubel FM et aL, and updates thereof). Antigen-binding fragments of antibodies described herein can be generated by any technique known to those of skill in the art. For example, Fab and F(ab')2 fragments described herein can be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). A Fab fragment corresponds to one of the two identical arms of a tetrameric antibody molecule and contains the complete light chain paired with the VH and CHI domains of the heavy chain. A F(ab')2 fragment contains the two antigen-binding arms of a tetrameric antibody molecule linked by disulfide bonds in the hinge region. Further, the antibodies or antigen-binding fragments thereof can also be generated using various phage display and / or yeast-based presentation methods known in the art. In phage display methods, proteins are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In particular, DNA sequences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or murine cDNA libraries of affected tissues). The DNA encoding the VH and VL domains are recombined together with a scFv linker by PCR and cloned into a phagemid vector. The vector is electroporated in E. coli and the E. coli is infected with helper phage. Phage used in these methods are typically filamentous phage including fd and Ml 3, and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII. Phage expressing an antibody or antigen-binding fragment thereof that binds to a particular antigen can be selected or identified with antigen, e.g., using labelled antigen or antigen bound or captured to a solid surface or bead. Examples of phage display methods that can be used to make the antibodies or fragments described herein include those disclosed in Brinkman U et al., (1995) J Immunol Methods 182: 41-50; Ames RS et al., (1995) J Immunol Methods 184: 177-186; Kettleborough CA et al., (1994) Eur J Immunol 24: 952-958; Persic L et al., (1997) Gene 187: 9-18; Burton DR &Barbas CF (1994) Advan Immunol 57: 191 -280; WO 90 / 02809, WO 91 / 10737, WO 92 / 01047, WO 92 / 18619, WO 93 / 1 1236, WO 95 / 15982, WO 95 / 20401, and WO 97 / 13844; and U.S. Patent Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743, and 5,969,108. A humanised antibody or antigen-binding fragment thereof can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGI, lgG2, lgG3 and lgG4. In an embodiment, the combination is administered to a coronary artery of the subject. In some embodiments, the combination is administered near or close to the site of blockage in the coronary artery. The coronary artery includes two main arteries, and the combination may be administered in one or both of the main coronary arteries. The two main coronary arteries are commonly referred to as the left main coronary artery (LMCA) which supplies blood to the left side of the heart muscle (the left ventricle and left atrium) and the right coronary artery (RMCA) which supplies blood to the right ventricle, the right atrium and the sinoatrial and atrioventricular nodes. LMCA and RMCA branch off into smaller artery branches: the left anterior descending artery and the circumflex artery, and the right posterior descending artery and the acute marginal artery as well as obtuse marginal, septal perforator, and diagonal branches of the coronary artery. The location of the site of blockage within the coronary artery can vary from patient to patient, although more frequently it is in the left coronary artery. The location of the administration may be assessed, for example by identifying and / or imaging the site of a blockage within the coronary artery of the subject. Identifying and / or imaging the site of blockage may include an angiogram and / or CT scan of a patient's heart. In an embodiment, the combination is administered to or near to the site of a blockage within the coronary artery of the subject. Thus, in an embodiment, the invention includes a prior step of identifying and / or imaging the site of a blockage within the coronary artery of the subject. Techniques for the imaging, detecting or localising a coronary artery blockage are known in the art, e.g. in https: / / www.mayoclinic.org / diseases-conditions / coronary-artery-disease / diagnosis-treatment / drc-20350619; https: / / www.mayoclinic.org / doppler-ultrasound / expert- answers / faq-20058452; or in Bansal et al. (Updates in the Management of Coronary Artery Disease: A Review Article, Cureus, published 16 December 2023; DOI: 10.7759 / cureus.50644; https: / / assets.cureus.com / uploads / review_article / pdf / 183942 / 20240724-319105-fhkkh0.pdf). Blockages of the coronary artery can be identified, for example, via a CT scan of the heart or a CT scan specifically conducted of the coronary artery. The CT scan may allow the identification of deposits or blockages, e.g. in form of calcium deposits in coronary arteries. The sensitivity of the test can be improved by intravenous administration of a contrast dye to the patient prior to the CT scan. For example, the dye may be administered via a catheter in a blood vessel. In some instances, the contrast dye can be directly injected into the coronary arteries using a cardiac catheterisation. An alternative technique for identifying a coronary artery blockage is the screening of the arteries using Doppler ultrasound. In this screening method, Doppler ultrasound is sent into the body. Reflection of the sound waves from interaction with red blood cells in the blood vessels of the artery is detected by an ultrasound transducer and allows the creation of images of internal structures of the coronary artery. This allows the detection of blockages or reduced blood flow within the coronary artery. In an embodiment, the combination is administered upstream of the site of blockage within the coronary artery. Methods and devices for administration of a drug such as an antibody to a coronary artery may include percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), intracoronary administration or local intramyocardial administration, as disclosed in Nanomedicine for Ischemic Cardiomyopathy, Progress, Opportunities, and Challenges, 2020, chapter 7, Aieneravaie et al.). Intracoronary delivery involves the direct infusion of therapeutics into the coronary arteries. Verma et al. reported the intracoronary administration of exogenous ATP to protect against ischemic injury in a rabbit model for Ml: liposomes carrying ATP were administered directly to the coronary artery (ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction; Pharm. Res. 2005;22:2115-2120. doi: 10.1007 / sll095-005-8354-x). In another example, Henry et al. disclose the intracoronary administration of recombinant human vascular endothelial growth factors to patients with coronary artery disease (Henry et al., American Heart Journal, volume 142, issue 5, 2001, p.872-880, https: / / www.sciencedirect.com / science / article / abs / pii / S0002870301001880). rhVEGF was administered to patients by two sequential intracoronary infusions, e.g. for a period of 10 minutes, at rates of 0.005 (n = 4), 0.017 (n = 4), 0.050 (n = 4), and 0.167 mg / kg / min (n = 3). The uptake of rhVEGF was monitored via pharmacokinetic sampling and hemodynamic monitoring, which were performed for 24 hours. In this case, the intracoronary infusion was further combined with radionuclide myocardial perfusion imaging performed before treatment and at 30 and 60 days after treatment. Follow-up angiograms were performed on selected patients at 60 days. In an embodiment, the combination is administered via a bypass, a catheter (microcatheter, angioplasty catheter), or a stent. In an embodiment, the invention comprises a step of monitoring a response of the subject after treatment with the therapeutic combination. For example, monitoring a response of the subject after administration may include detecting the onset of angiogenesis and / or myocardial tissue survival. The therapeutic agents, i.e., the SULF1, ANG2 and SULF2 inhibitors (that may be anti-SULFl, anti-ANG2 and anti-SULF2 antibodies) and the ANG1 (and enhancer), used in the treatments described herein, can be formulated into pharmaceutical compositions suitable for administration. The pharmaceutical compositions may comprise pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient, as used herein, includes, but are not limited to, any and all solvents, dispersion media, or other liquid vehicles, dispersion or suspension aids, diluents, granulating and / or dispersing agents, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, binders, lubricants or oil, colouring, sweetening or flavouring agents, stabilisers, antioxidants, antimicrobial or antifungal agents, osmolality adjusting agents, pH adjusting agents, buffers, chelants, and / or bulking agents, as suited to the particular dosage form desired. Various excipients for formulating pharmaceutical compositions and techniques for preparing the composition are known in the art (see Remington: The Science and Practice of Pharmacy, 23rd Ed., A. Adejaro (ed.) (Academic Press), 2022). Any of the therapeutic agents described herein may be in the form of a pharmaceutically acceptable salt. In some embodiments, such salts are derived from inorganic or organic acids or bases (Remington). Examples of suitable acid addition salts include acetate, adipate, alginate, aspartate, benzoate, besylate (benzene sulfonate), bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3 -phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Examples of suitable base addition salts include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine; and salts with amino acids such as arginine, lysine, and the like. The pharmaceutical compositions may comprise pharmaceutically acceptable carriers. As used herein, "pharmaceutically acceptable carrier" refers to a material that is compatible with a recipient subject (a human) and is suitable for delivering an active agent to the target site without terminating the activity of the agent. The toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk / benefit ratio for the intended use of the active agent. Pharmaceutically acceptable carriers that may be used in these compositions include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates or carbonates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. The pharmaceutical compositions for use in the treatments of the present disclosure may be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilising, or emulsifying processes, among others. Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. Formulations may contain stabilisers, pH modifiers, surfactants, solubilising agents, bioavailability modifiers and combinations of these. These pharmaceutical compositions are typically formulated for pharmaceutical administration to a human being. Such compositions may be administered for example, parenterally, or via an implanted reservoir. The term "parenteral" as used herein includes intravenous or intra-articular injection or infusion techniques. The compositions may be administered in a local rather than systemic means, such as administration (e.g., by injection) to the coronary artery, e.g. at the site of a blockage. Pharmaceutical formulations may be prepared as gels, liquid suspensions or solutions using a liquid, such as an oil, water, an alcohol, and combinations of these. Solubilising agents such as cyclodextrins may be included. Pharmaceutically suitable surfactants, suspending agents, or emulsifying agents, may be added for oral or parenteral administration. Suspensions may include oils, such as peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension preparations may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides. Suspension formulations may include alcohols, such as ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol; ethers, such as poly(ethyleneglycol); petroleum hydrocarbons such as mineral oil and petrolatum; and water. Sterile injectable forms of these pharmaceutical compositions may be aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as sorbitan alkyl esters, such as Tweens or Spans, and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. Compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers. In one embodiment, one or more of the treatment agents is formulated as a solution for intravenous infusion. In some embodiments, the agent is formulated in a solution with a buffering agent or a pH modifying agent, and a cyclodextrin, such as a beta-cyclodextrin. In one embodiment, the solution includes phosphoric acid and Captisol (betadex sulfobutyl ether sodium) in water. In an embodiment, the combination is administered after the occurrence of the myocardial infarction in the subject. Thus, in an embodiment, the invention includes a prior step of determining that the subject has suffered a myocardial infarction. Myocardial infarction (Ml), also defined as myocardial necrosis in a clinical setting consistent with myocardial ischemia, can be detected by electrocardiography (ECG), by the detection of presence or absence of certain biomarkers, or in combination thereof. The detection of Ml is well-known in the art. For example, Thygesen et al. provide a summary on definitions and available types of diagnosis in the field of myocardial infarction (Fourth Universal Definition of Myocardial Infarction (2018) - ScienceDirect, Journal of the American College of Cardiology, volume 72, issue 18, 30 October 2018, pages 2231-2264): For example, the detection of Ml using biomarkers conditions can be satisfied by a rise of cardiac biomarkers, such as cardiac troponin [cTn], above the 99th percentile of the upper reference limit (URL) and detection of one or more of the following symptoms: • Symptoms of myocardial ischemia • ECG changes indicative of new ischemia (significant ST / T changes or left bundle branch block) • Development of pathologic Q waves • Imaging evidence of new loss of myocardium or new regional wall motion abnormality • Angiography evidence of intracoronary thrombus These criteria may allow the diagnosis of Ml during and after percutaneous coronary intervention or coronary artery bypass grafting (and of less relevance in the context of the present invention, as the cause of sudden death). Ml can be commonly classified into 5 types based on aetiology and circumstances: • Type 1: Spontaneous Ml caused by ischemia due to a primary coronary event (e.g., plaque rupture, erosion, or fissuring; coronary dissection) • Type 2: Ischemia due to increased oxygen demand (e.g., hypertension), or decreased supply (e.g., coronary artery spasm or embolism, arrhythmia, hypotension) • Type 3: Related to sudden unexpected cardiac death (again, of less relevance in the context of the present invention). • Type 4a: Associated with percutaneous coronary intervention (signs and symptoms of myocardial infarction with cTn values >5 x 99th percentile URL) • Type 4b: Associated with documented stent thrombosis • Type 5: Associated with coronary artery bypass grafting (signs and symptoms of myocardial infarction with cTn values >10 x 99th percentile URL) One method of testing for Ml involves the repeated analysis of blood samples for their cardiac troponin (CTn) content, e.g. at hourly sampling intervals up to 6 hours. Sampling beyond 6 hours may be necessary if further ischemic episodes occur or in high-risk patients. To establish a diagnosis of an acute Ml, a rise and / or fall in cTn values with at least one value above the 99th percentile URL may be coupled with a high clinical and / or ECG likelihood of myocardial ischemia. As described by Scirica et al. (B.M. Scirica, D.A. Morrow, A. Budaj, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome, J. Am. Coll. Cardiol., 53 (2009), pp. 1411-1421), electrocardiographic detection of Ml is commonly used in the diagnosis of patients with suspected Ml. Acute myocardial ischemia is often associated with dynamic changes in ECG waveform and serial ECG acquisition can provide critical information, particularly if the ECG at initial presentation is non-diagnostic. Recording several standard ECGs with fixed electrode positions at 15 to 30 min intervals for the initial 1 to 2 h, or the use of continuous computer-assisted 12-lead ECG recording (if available) to detect dynamic ECG changes, is reasonable in patients with persistent or recurrent symptoms or an initial non-diagnostic ECG. For example, ECG evidence of myocardial ischemia in the distribution of a left circumflex artery, e.g. in form of the detection of isolated ST-segment depression >0.5 mm in leads V1-V3 may indicate left circumflex occlusion. When the magnitudes of J-point elevation in leads Vzand Vsare registered from a prior electrocardiogram, new J-point elevation >1 mm (as compared with the earlier electrocardiogram) should be considered an ischemic response. Other non-invasive imaging techniques for the detection of Ml as an alternative or in addition to ECG may include: • radionuclide imaging, e.g. myocardial perfusion scintigraphy (MPS) using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) with radiopharmaceuticals, • cardiac magnetic resonance (CMR), e.g. using paramagnetic contrast agents, or • computed tomography (CT) as disclosed by Stillman AE, Oudkerk M, Bluemke D, et al. (Assessment of acute myocardial infarction: Current status and recommendations from the North American Society for Cardiovascular Imaging and the European Society of Cardiac Radiology. Int. J. Cardiovasc Imaging. 2011;27:7-24). Typically, and in some embodiments, the combination is administered to the subject within 3 days of the myocardial infarction. In some embodiments, the combination is administered within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours of the myocardial infarction. In an embodiment, the combination is administered to the subject no more than 3 days after the myocardial infarction. In some embodiments, the combination is administered no more than 72 hours or no more than 48 hours or no more than 24 hours or no more than 12 hours after the myocardial infarction. In an embodiment, dosages of the combination to be administered depend on the size of the blocked artery. For example, a dosage may be 100 ng for small coronary arteries. Dosages of the combination may be defined by in vivo analyses. Commonly, a reference vessel diameter (RVD) of <2.5 mm measured with intracoronary imaging (ICI) is regarded as the standardised definition of small vessel coronary artery disease (CAD). A large size for a coronary artery diameter typically refers to a diameter exceeding 8mm or four times the reference vessel diameter. In any event, suitable dosages will be determined by the physician, as known in the art. In an embodiment, the subject is also administered another treatment of myocardial infarction. In some embodiments, the other myocardial infarction treatment comprises one or more of: administration of an antithrombic agent such as aspirin, heparin, bivalirudin, enoxaparin, or clopidogrel; administration of a nitrate such as isosorbide mononitrate or nitroglycerin; administration of a beta blocker such as bisoprolol or metoprolol; administration of an ACE inhibitor; administration of a calcium channel blocker such as amlodipine or diltiazem; cardiac rehabilitation treatment; oxygen therapy; pain management; thrombolytic therapy; percutaneous coronary intervention or coronary artery bypass graft. Additional treatments for myocardial infarction and ischemic heart disease that may be suitable for use in conjunction with the invention include, for example, one or more treatments of the following (https: / / www.mayoclinic.org / diseases-conditions / myocardial-ischemia / diagnosis-treatment / drc-20375422): • In some embodiments, antithrombic agents such as aspirin and / or other anti-platelet agents ('blood thinners'), statins, beta blockers, nitrates, ACE inhibitors, calcium channel blockers etc. are administered to a subject (Willard et al., The use of Aspirin in Ischemic Heart disease, N. Engl. J. Med. 1992, 327:175-181; DOI: 10.1056 / NEJM199207163270308; Sueta et al., Clinical roles of calcium channel blockers in ischemic heart diseases, Hypertension Research volume 40, pages 423-428 (2017)). • Treatment of myocardial infarction and ischemic heart disease may include providing a subject with a coronary artery bypass graft via surgery. Creating of a bypass graft from a blood vessel from another area of the body can bypass the narrowed artery to improve blood flow (Ross et al., Ischemic heart disease: An overview, The American Journal of Cardiology, Volume 36, issue 4, 6 October 1975, 496-505; doi: 10.1016 / 0002-9149(75)90901-7). The present invention may prevent the need for coronary artery bypass graft surgery. • Treatment of myocardial infarction and ischemic heart disease may include angioplasty. This minimally invasive treatment can include the insertion and inflation of a small balloon into the artery to improve blood flow, e.g. by widen narrowed or blocked arteries (Michael etal., Circulation, Volume 106, issue 23, December 2002, pages el87-el90; doi: 10.1161 / 01.CIR.0000044747.37349.64). • Treatment of myocardial infarction and ischemic heart disease may include stenting. Stenting is a minimal-invasive procedure where a small, expandable mesh tube (stent) is inserted into a narrowed or blocked artery. Stenting may be combined with the treatment by angioplasty. • Treatment of myocardial infarction and ischemic heart disease may include lifestyle changes. Specifically, treatment of myocardial infarction and ischemic heart disease may include nicotine replacement therapy, weight loss therapy, physical exercise and medical nutrition therapy such as glucose control for subjects suffering from diabetes mellitus. In an embodiment, the subject to be treated is a mammal, preferably a human. In an embodiment, the combination an inhibitor of SULF1, an inhibitor of ANG2, and ANG1, promotes growth and / or angiogenesis of coronary artery endothelial cells. The present invention thus provides a combination of an inhibitor of SULF1, an inhibitor of ANG2, and ANG1 or ANG1 enhancer, for use in promoting angiogenesis of coronary artery endothelial cells ex vivo., e.g. in cell culture. The present invention further provides a method of promoting angiogenesis in coronary artery endothelial cells, the method comprising administering to the cells a combination of an inhibitor of SULF1, an inhibitor of ANG2, and ANG1. In an embodiment, the combination is administered to a coronary artery of a subject in vivo. In an embodiment, the subject has suffered a myocardial infarction. In an embodiment, the combination is administered after the occurrence of the myocardial infarction in the subject. The present invention also provides a pharmaceutical composition comprising an inhibitor of SULF1, an inhibitor of ANG2, and ANG1, and a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides a pharmaceutical composition comprising an inhibitor of SULF1, an inhibitor of ANG2, and ANG1 ligand, and a pharmaceutically acceptable carrier, diluent or excipient, for use in medicine, i.e., for use as a medicament. Thus, the present invention provides a pharmaceutical composition comprising an anti-SULFl antibody, an anti-ANG2 antibody, and ANG1, and a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides a pharmaceutical composition comprising an anti-SULFl antibody, an anti-ANG2 antibody, and ANG1, and a pharmaceutically acceptable carrier, diluent or excipient, for use in medicine, i.e., for use as a medicament. In an embodiment, the pharmaceutical compositions may further comprise an inhibitor of SULF2, which may be an anti-SULF2 antibody. Method aspects of the invention include: 1A. A method of treating myocardial infarction in a subject in need thereof, the method comprising administering to the subject a combination of an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1). IB. A method of treating or preventing ischemic heart disease in a subject following a myocardial infarction, the method comprising administering to the subject a combination of an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1). 2. The method according to aspect 1, wherein the inhibitor of SULF1 is an anti-SULFl antibody. 3. The method according to aspect 1, wherein the inhibitor of ANG2 is an anti-ANG2 antibody. 4. The method according to aspect 1, wherein the ANG1 is an ANG1 polypeptide. 5. The method according to any of aspects 1-4, further comprising administering an inhibitor of SULF2 to the subject. 6. The method according to aspect 5, wherein the inhibitor of SULF2 is an anti-SULF2 antibody. 7. The method according to any of aspects 1-6, wherein the inhibitor of SULF1, the inhibitor of ANG2, the ANG1, and / or the inhibitor of SULF2 are administered to a coronary artery of the subject. 8. The method according to any of aspects 1-7, wherein the method comprises a prior step of determining that the subject has suffered a myocardial infarction. 9. The method according to any of aspects 1-8, wherein the combination is administered to the site of a blockage within the coronary artery of the subject. 10. The method according to any of aspects 1-8, wherein the combination is administered upstream of the site of blockage within the coronary artery. 11. The method according to any of aspects 1-10, wherein the combination is administered via a bypass, catheter (microcatheter, angioplasty catheter), or a stent etc. 12. The method according to any of aspects 1-11, wherein the method further comprises a step of identifying and / or imaging the site of a blockage of a coronary artery in the subject. 13. The method according to aspect 12, wherein step of identifying and / or imaging the site of a blockage of a coronary artery in the subject comprises using a method selected from a group consisting of: imaging, guidance, fluorescence and ultrasound methods. 14. The method according to any of aspects 1-13, wherein the method comprises a step of monitoring a response of the subject after treatment with the combination. 15. The method according to any of aspects 1-14, wherein the combination is administered in the form of a gel. 16. The method according to any of aspects 1-15, wherein the combination is administered after the occurrence of the myocardial infarction in the subject. 17. The method according to aspect 16, wherein the combination is administered within 3 days of the myocardial infarction. 18. The method according to aspect 17, wherein the combination is administered within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours of the myocardial infarction. 19. The method according to any of aspects 1-18, wherein the subject is administered another treatment of myocardial infarction or ischemic heart disease. 20. The method according to aspect 19, wherein the other treatment comprises administration of an antithrombic agent, such as aspirin. 21. The method according to any of aspects 1-20, wherein the combination promotes growth and / or angiogenesis of coronary artery endothelial cells. 22. A method of promoting angiogenesis in coronary artery endothelial cells, the method comprising administering to the cells a combination of an inhibitor of SULF1, an inhibitor of ANG2, and ANG1. 23. The method according to aspect 22, wherein the inhibitor of SULF1 is an anti-SULFl antibody. 24. The method according to aspect 22, wherein the inhibitor of ANG2 is an anti-ANG2 antibody. 25. The method according to aspect 22, wherein the ANG1 is an ANG1 polypeptide. 26. The method according to any of aspects 22-25, further comprising administering an inhibitor of SULF2 to the cells. 27. The method according to aspect 26, wherein the inhibitor of SULF2 is an anti-SULF2 antibody. 28. The method according to any of aspects 22-27, wherein the combination is administered to a coronary artery of a subject in vivo. 29. The method according to aspect 28, wherein the subject has suffered a myocardial infarction. 30. The method according to aspect 29, wherein the combination is administered after the occurrence of the myocardial infarction in the subject. 31. The method according to aspect 30, wherein the combination is administered within 3-4 days of the myocardial infarction. 32. The method according to aspect 31, wherein the combination is administered within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, or 72 hours of the myocardial infarction. 33. The method according to any of aspects 22-27, wherein the combination is administered to coronary artery endothelial cells in vitro. The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge. All patents and publications cited herein are fully incorporated by reference herein in their entirety. The following examples are presented in order to illustrate some embodiments of the invention more fully. They should, in no way be construed, however, as limiting the broad scope of the invention. EXAMPLES Heart failure following myocardial infarction (Ml) remains one of the major causes of death posing a serious therapeutic challenge. VEGF is a key regulator of angiogenesis and VEGF-based proangiogenic therapy offers a promising strategy to treat patients with acute Ml since new micro-vessel formation has the potential to salvage ischemic myocardium at an early stage post-Mi that could prevent progression to heart failure. VEGF is also one of the early factors upregulated, albeit at low level, at the onset of ischemia that plays a critical role in the initiation of the angiogenic response. However, the delivery of a single growth factor on its own is unlikely to restore angiogenesis due to the requirement for additional less well characterised factors and their regulatory control. The present study shows that angiogenesis in myocardium is unlikely to be reactivated by VEGF alone and that it has another layer of control relating to the non-regenerating nature of adult cardiomyocytes in comparison with other regenerating tissues that, for example, cope with highly prevalent skin / dermal tissue injuries. Morphological endothelial cell diversity is well documented to highlight endothelial cell type differences in microvascular versus macrovascular blood vessels
[15] but their VEGF responses or their precise VEGF cell signalling cascades have not been adequately characterised in endothelial cells of different tissue types. Tissue type specific endothelial cell characteristics do not only relate to endothelial cell biology but also to the biology of surrounding extracellular matrix (ECM) and host cell environment that contribute to the angiogenic cell signalling cascades determining tissue type specific specialisation of endothelial cells. The inventor's earlier study demonstrated context dependent divergent arterial versus venous endothelial cell type angiogenic responses [7], In the present study, it has been found that adult coronary artery endothelial cells are highly responsive in comparison to aortic endothelial cells and demonstrate a significant difference between endothelial cells of coronary arteries and aorta. A variety of new therapies have been pursued to mitigate cardiac damage after ischemic events, but no studies have shown any significant effect of VEGF angiogenic therapy in the ischemic myocardium
[10] , Recently developed angiogenic and anti-apoptotic therapies target the interface between the perfused and the non-perfused areas in the border zone to induce angiogenesis but inhibit cardiomyocyte apoptosis. The experimental evidence for the success of these therapies is limited. Angiogenesis is known to first initiate in the necrotic granulation tissue, the central scar devoid of cardiomyocytes but neovascularisation in the partially ischemic border zone amenable to recovery to restore myocardial function fails with delayed response as angiogenesis in this region does not progress until cardiomyocytes in there die first This further highlights some inhibitory activity of adult card io myocytes unlike fetal angiogenesis
[11] , While SULF1 / SULF2 responses vary in endothelial cells of different tissue types [7], the angiogenic responses have also been shown to vary in a regional way in the same tissue. For example, the angiogenesis has been shown to initiate in the fibrotic area devoid of cardiomyocytes but not in the ischemic myocardial region highlighting regional angiogenic inhibition by cardiomyocyte rich region when compared to cardiomyocyte deprived scar zone
[16] , Only a mechanistic understanding of Ml angiogenic response therefore can provide appropriate therapeutic opportunities to improve heart function
[16] . The inventor's previous studies demonstrated context dependent regulation of angiogenesis [7] although they did not show any relationship to arterial versus venous cells. The present study was undertaken to investigate the SULF1 and SULF2 mediated angiogenic regulation in primary coronary artery endothelial cells compared with angiogenic regulation of aortic endothelial cells. MATERIALS AND METHODS Cell Culture and SULF1 / SULF2 Transfection Primary human coronary artery endothelial cells, primary human aortic endothelial cells, and a human aortic endothelial cell line (HAEC) were purchased from PromoCell (Germany). These cells were grown in MV2 medium with supplements and 10% FCS. These cells were used to examine the effect of SULF1 and SULF2 overexpression in these cell types. Over-expression of SULF1 or SULF2 genes in these cells was achieved using BioRad transfection reagent (Bio-Rad Laboratories Ltd, Maxted Road, Hemel Hempstead, HP2 7DX, UK) as previously described
[22] , Transfection with an EGFP expression vector or with pcDNA3 were used as controls. Such cells transfected for at least 10 days were used for all in vitro analyses. For in vitro proliferation assays, 5,000 cells / well were seeded in multiple 48-well plates and fixed for Sulforhodamine B (SRB) analyses following 4 days of growth. Cultured cells on 48-well plates were fixed using trichloroacetic acid and stained with SRB for 30 minutes, washed and dried before the bound dye was solubilised in 10 mM unbuffered Tris base and the absorbance measured at OD 565 nm
[23] , The amount of dye extracted provides a measure of cell mass and the number of cells in a sample if the cells are approximately similar in size. For each sample, a minimum of three technical replicates were performed for each stage, and each experiment was repeated three times. For cell migration assays, 5000 cells were seeded into each insert of an Ibidi Culture dish with 3-well silicone inserts for overnight growth. The insert was removed once the cells were confluent the next day and imaged at 0 and 8 h or also at 20 h time intervals as appropriate for different cell lines. RT-PCR Analysis Total RNA was prepared from control (EGFP and pcDNA3 transfected cells) and SULF1 and SULF2 transfected cells using Trizol (Invitrogen) according to the manufacturer's instructions. RNA integrity was assessed by electrophoresis using Syber safe staining and OD260 / OD280 nm absorption ratio (>1.95)
[24] , Total RNA (1 pg) for each sample was reverse-transcribed into cDNA with Superscript II reverse transcriptase (Invitrogen) using random primers (Invitrogen) for RT-PCR analysis with 35 PCR amplification cycles using the following primers: SULF1: 5'-CCGATGATCAAGATGTGGAGC-3', and 5'-GCATTGGTCCTGTGTACT GC-3'; SULF2: 5'-CAGGTTTCAGAGGGACCGCAG-3', and 5'-GAGTCGTCCACCGACATGAGG-3'; SMAD2: 5'-AACAGAACTTCCGCCTCTGG-3', and 5'-ACCGTCTGCCTTCGGTATTC-3'; SMAD3: 5'-GGAGACACATCGGAAGAGGC-3', AND 5'-CCCTCCCCATCCCAAGTCTA-3'; ALK5: 5'-GGGGCGACGGCGTTACAGTG 1 1 ICIGCCAC-3', and 5'-TGAGATGCAGACGAAGCACACTGGTCCAGC-3'; TGFpl: 5'-AAGTGGATCCACGAGCCCAA-3', and 5'-GCTGCACTTGCAGGAGCGCAC-3'; TGFpRII: 5'-CACCGCACGTTCAGAAGTC-3', and 5'-GAGGCTGATGCCTGTCACTT-3'; SMAD1: 5'-GAGACAGCTTTATTTCACCATATCC-3', and 5'-CATAGTAGACAATAGAGCACCAGTG 1 1 1 1-3'; SMAD5: 5'-CGGTAGCCACTGACTTTGAGTTAC-3', and 5'-AGCTGAAATGGACTTCCTGGTC-3'; VEGF: 5'- GAAGTGGTGAAGTTCATGGATGTC-3', and 5'-CGATCGTTCTGTATCAGTCTTTCC-3'; (detecting 541bp VEGF165 and 408bp VEGF121 fragments
[25] ) VEGFR1: 5'-CTG AG AACAACGTGGTG AAG ATT-3', a nd 5'-CTGACATCATCAGAGCTTCCTGA-3'; ANG1: 5'-GGAAGTCTAGATTTCCAAAGAGGC-3', and 5'-CTTTATCCCATTCAGTTTTCCATG-3'; ANG2: 5'- GCCACAACCATGATGATCC-3', and 5'-TTCTTGGTTGTGACAGCAGC-3'; TIE2: 5'-TGCCCAGATATTGGTGTCCT-3', and 5'-CTCATAAAGCGTGGTATTCACGTA-3'; p-ACTIN: 5'-CTATGAGCTGCCTGACGGTC-3', and 5'-AGTTTCATGGATGCCACAGG-3'. RT-PCR fragments were separated in 1% agarose gels using 0-actin fragments to normalise the sample loading. All RT-PCR experiments were repeated at least three times. Expression levels were quantified using Image J and statistical analysis was performed using ANOVA, where data depicting a p value <0.05 were considered statistically significant. Immunocytochemistry Control and experimental primary coronary artery and aortic endothelial cells were grown on Lab-Tek glass slides or Ibidi 12-well chamber slides and fixed in 4% paraformaldehyde for 15 min. before staining with different antibodies as previously described
[26] , This involved incubation of fixed cells with permeabilisation buffer for 15 min. at room temperature followed by incubation with 10% foetal calf serum (FCS) for 30 min. before treatment with different primary antibodies at different dilutions, e.g., SULF1 (1 / 200), SULF2 (1 / 100), as recommended by the suppliers. Binding of rabbit primary antibodies was detected using streptavidin Alexa Fluor 594 or Alexa Fluor 488 fluorochrome bound to biotin-linked goat anti-rabbit immunoglobulins as previously described
[27] ,
[32] , The binding of mouse monoclonal antibodies was detected using goat anti-mouse immunoglobulins linked to Alexa Fluor 488 or Alexa Fluor 594 fluorochrome. Sections treated with pre-immune rabbit and mouse sera were similarly incubated with fluorochrome-labelled secondary antibodies as controls (not shown). All primary antibody incubations overnight at 4°C were followed by secondary antibody incubations for 1 hour each at room temperature. Following four PBS washes between and after each incubation, labelled tissue sections were mounted in a polyvinyl alcohol mounting medium with DABCO and 2.5 pg / mL DAPI for nuclear visualisation to photograph images using a Leica DM4000B fluorescent microscope. EXAMPLE 1: SULF1 / SULF2 FUNCTIONAL DIVERGENCE IN CORONARY ARTERY ENDOTHELIAL CELLS Summary: SULF1 / SULF2 functional divergence was demonstrated in coronary artery endothelial cells. VEGF and ANG1 and TGF0 modulation were inhibited by SULF1, whereas ANG2 is promoted by SULF2. Figure 6A is an illustration confirming SULF1 and SULF2 expression by immunocytochemistry following transfection in coronary artery endothelial cell. Figures IB and 7C illustrate gene expression levels of various angiogenic molecules, TGF0 and VEGF cell signalling associated components, as detected by RT-PCR in coronary artery endothelial cells following SULF1 and SULF2 over-expression. Full length SULF1 or SULF2 was overexpressed in primary human coronary endothelial cells to compare their cell signalling responses with untreated cells. RT-PCR analysis of control primary coronary artery endothelial cells showed little or no SULF1 or SULF2 expression in but low-level expression of both these enzymes could be detected in a small proportion of cells using an immunocytochemical procedure. As expected, transfection of primary coronary artery endothelial cells with full length SULF1 or SULF2 resulted in high level expression of these enzymes using both RT-PCR and immunocytochemical procedures (Figure 1). RT-PCR analysis also detected a low level expression of VEGF in control primary coronary artery endothelial cells that was completely inhibited by SULF1 over-expression, but was maintained at a slightly reduced level with SULF2 over-expression. Low levels of ANG1 were apparent only in control primary coronary artery endothelial cells since ANG1 expression was inhibited in both SULF1 and SULF2 transfected cells. ANG2 was barely detectable in control primary coronary artery endothelial cells. This was not affected in SULF1 overexpressing cells whereas marked ANG2 upregulation was observed in SULF2 over-expressing cells. SMAD2, TGFpi and TG F|3 RI I were easily detectable in control primary coronary artery endothelial cells. SMAD2 and TGF|3RII were inhibited with SULF1 over-expression but maintained in SULF2 over-expressing cells with only a slight reduction in their levels. TGFpi did not appear to be affected by either SULF1 or SULF2 over-expression (Figures 1A-1C). SULF1 and SULF2 signalling function in coronary artery endothelial cells thus diverged for some signalling pathways but not others. Newly isolated primary coronary endothelial cells show the presence of VEGF that is inhibited by SULF1 over-expression but not by SULF2. SULF1 over-expression in such cells does not only inhibit VEGF but also the angiogenic enhancer ANG1 and TGF0 signalling This is not the case for the angiogenic inhibitor ANG2. SULF2 over-expression in such cells maintains both VEGF and TGF0 signalling but markedly promotes the angiogenic inhibitor ANG2. Failure to maintain adequate blood supply can result in loss of myocardial contractility as the muscle tissue is replaced by fibrosis or scar tissue. Thus, fibrosis reduction may help maintain cardiac muscle function, EXAMPLE 2: EFFECT OF HYPOXIA ON PRIMARY CORONARY ARTERY ENDOTHELIAL CELLS Summary: Hypoxia not only upregulates some SULF1, SULF2, VEGF and TGF0 signalling components but also marked ANG2 upregulation and complete ANG1 inhibition in primary coronary artery endothelial cells. Figure 2 (Al, A2, Bl and B2) illustrates the effect of chemical hypoxia (lOOuM C0CI2) over time (3hr-96hr) in newly isolated primary coronary artery endothelial cells on SULF1, SULF2 and some TGF0 and VEGF cell signalling associated components: To determine how hypoxia in vitro may affect VEGF or TGF0 cell signalling in primary coronary artery endothelial cells, confluent layers of such cells in 60 mm petri dishes were exposed to lOOpM C0CI2 for different lengths of time (3 hours, 24 hours, 72 hours and 96 hours). Their effect on the expression of SULF1 / SULF2, VEGF, angiopoietins and TGF0 cell signalling was examined using RT-PCR analysis that was quantified by densitometric analyses. Significant level of SULF1 upregulation was observed at 24 hours of hypoxia with levels reducing at 72 hours and 96 hours exposure (Figure 2). Low level SULF2 activation was not observed until 24 hours post hypoxia although its levels increased a little further at 72 hours being still apparent at 96 hours. VEGF levels increased gradually even at 3 hours with its maximum expression at 72 hours. ANG1 being apparent in only control primary coronary artery endothelial cells, however, became undetectable within 3 hours following chemical hypoxia while ANG2 was markedly increased even at 3 hours and subsequent time points following chemical hypoxia. Hypoxic exposure of primary coronary artery endothelial cells also activated increasing levels of Smad2 and TGF0RII but maintained very low levels of Smad3. TGF01 activation in primary coronary artery endothelial cells was only observed during early time points of 3 hour and 24 hours of hypoxia. Smad 5 but not Smadl (not shown) was immediately activated even at 3 hour and subsequent time points (Figures 2A-2B). Newly isolated primary coronary endothelial cells under hypoxia gradually increase some VEGF expression and SULF1 / SULF2 levels but markedly and rapidly enhance high levels of angiogenic inhibitor ANG2 while rapidly inhibiting angiogenic enhancer ANG1. Hypoxia also enhances TGF0 signalling (and possibly some BMP signalling). Hypoxic responses, however, are not static as some cell signalling pathways are differentially inhibited or maintained in older coronary artery endothelial cells. EXAMPLE 3: EFFECT OF SULF1 NEUTRALISING ANTIBODIES This experiment is to demonstrate the effect of SULF1 neutralising antibodies on VEGF activity in SULF1 over-expressing primary coronary artery endothelial cells. To ascertain how effectively SULF1 inhibits VEGF, different amounts of VEGF, (50 ng-100 ng) are added to SULF1 over-expressing primary coronary artery endothelial cells as described in the inventor's earlier study of myogenic cells
[14] , RT-PCR analysis demonstrates the neutralisation of SULF1 enzyme and how well it protects VEGF activity by triggering new blood vessel formation / angiogenesis. EXAMPLE 4: EFFECT OF ANG1 AND ANG2 This experiment is to demonstrate the effect of ANG1 and ANG2 on angiogenic cell signalling in coronary artery endothelial cells. To ascertain how effectively the inclusion of angiogenic ligand ANG1, and ANG2 inhibition by anti-ANG2 antibody, promotes angiogenesis in coronary artery endothelial cells, the agents are added to primary coronary artery endothelial cells as described above. Analysis demonstrates the how well the inclusion of angiogenic ANG1, and ANG2 inhibition by anti-ANG2 antibody, promote angiogenesis by triggering new blood vessel formation. EXAMPLE 5: RESPONSES OF PRIMARY CORONARY ARTERY AND AORTA ENDOTHELIAL CELLS This experiment is to demonstrate the differential responses of primary coronary artery endothelial cells to changes in VEGF, TGFP and their inhibitors, and highlights their interdependent cell signalling and SULF1 / SULF2 regulation. Coronary Artery Figures 3A, Bl, and B2 and 3C illustrate the response of newly isolated primary coronary artery endothelial cells to sulfation / de-sulfation and some selected growth factors and their inhibitors. Figures 2A and 2B illustrate gene expression levels of various angiogenic molecules in coronary artery endothelial cells in response to hypoxia at various time points. Figures 8A and 3B illustrate gene expression levels of various angiogenic molecules in coronary artery endothelial cells in response to assorted treatments. Figure 3C is an illustration confirming SULF1 and SULF2 expression in coronary artery endothelial cells in response to differential cell signalling exposure. Unlike in HMecl cells [7], the inventor has shown that SULF1 induction in primary coronary artery endothelial cells that inhibits both VEGF and TGF0 cell signalling. The inventor further examined the effect of exposing such cells to VEGF andTGFP or their inhibitors for 48 hours on SULF1 / SULF2 signalling pathways that they affect. These treatments also included exposure to physiological concentrations of 8 mM sodium sulfate for global sulfation and 8 mM sodium chlorate for total de-sulfation to compare the effects of chemical sulfation and desulfation. The control primary coronary artery endothelial cells showed quite low or barely detectable levels of SULF1, SULF2 and most VEGF and TGF0 cell signalling components. The addition of 8mM sodium sulfate further inhibited the expression of such cell signalling components while 8mM NaCIOs generally increased their expression. SULF1 / SULF2 expression, however, was upregulated by exposure to not only VEGF165 but also to a lower level by VEGF120 as well as both ANG1 and ANG2. The addition of TGFpl inhibited both SMAD2, SMAD3, ALK5 and SMAD1 but not SMAD5. Exposure of these cells to VEGF, TGF01 or their inhibitors thus further highlights their endothelial cell type-specific responses and integral growth factor interactions to regulate net VEGF and TGF0 cell signalling activities. An experiment to demonstrate the response of primary coronary endothelial cells to some growth factors and their inhibitors showed that although VEGF is inhibited by SULF1, VEGF exposure to these cells does not only promote SULF1 and SULF2 levels but also promotes VEGF, possibly as their response to counteract SULF1 / SULF2 activities, regulating each other's activities. The levels of ANG1 and ANG2 were also generally similar but differentially regulated by such growth factors and their inhibitors. SMAD3 in contrast was significantly activated in response to such additions while it was barely detectable upon hypoxia as was SMAD1. Cell signalling regulation thus appears highly context dependent and dynamic. Aorta The inventor has also observed that, unlike coronary artery endothelial cells, neither SULF1 or SULF2 over-expression in human aortic endothelial cells (HAEC cells) produced any significant effect on VEGF or TGF0 cell signalling (data not shown). HAEC cells showed none or barely detectable levels of SULF1 but low level SULF2 expression using an immunocytochemical procedure, but not using RT-PCR analysis. Unlike coronary artery endothelial cells, human aortic endothelial cells (HAEC) also did not show any significant expression of VEGF or VEGFR1 detectable by RT-PCR that were relatively unresponsive to SULF1 or SULF2 over-expression. Transfection of HAEC cell line cells with SULF1 or SULF2 DNA did not induce the expression VEGF orTGFP cell signalling components using RT-PCR analyses. The treatment of HAEC cells with growth factors or their inhibitors to chemical changes in sulfation did not induce any SULF1 under such conditions while low level SULF2 was maintained in control and VEGF120 treated cells and also in TGF01 treated cells. High levels of TGF0 cell signalling components, however, were maintained in both SULF1 and SULF2 transfected HAEC cells. Highest levels of SMAD2 and SMAD5 expression were observed in SULF2 transfected untreated and VEGF165 treated cells. HAEC: Hypoxia SULF1 is absent and not induced by hypoxia. VEGF is absent and not induced by hypoxia. SULF2 is present but goes down with hypoxia. SMAD2 is present at low levels and not significantly affected by hypoxia. SMAD5 is present but goes down with hypoxia. CD31 is present at high levels but gradually goes down with hypoxia. TGFpi is present but inhibited by hypoxia. Coronary artery endothelial cells Figure 9A relates to coronary arterial endothelial cells and illustrates that despite short transient VEGF inhibition during early phase of 1-3 days, SULF1 expression supports the level of cell mass / growth in the presence of low level (control) or increased SULF1 expression during different phases of growth and differentiation or ageing. Figure 10B relates to coronary arterial endothelial cells and illustrates the level of cell migration in the presence of little (control) or increased SULF1 expression during different stages of cellular maturity / ageing. Summary Following transient SULF1 mediated VEGF inhibition during early coronary endothelial cell proliferation, the levels of SULF1 mediated cell signalling are dynamically and tightly regulated during endothelial cell migration, differentiation, growth, and cell survival. For example: 1. Unlike untreated control primary coronary artery endothelial cells, SULF1 overexpression promotes cell migration during hypoxic injury. 2. Unlike untreated control primary coronary artery endothelial cells, SULF1 over expression also promotes cell differentiation and growth of such cells during hypoxic injury. 3. Unlike untreated control primary coronary artery endothelial cells, SULF1 over expression maintains cell survival for longer period of time following hypoxic damage. 4. The levels of many cell signalling pathways in both untreated and SULF1 over-expressing coronary primary endothelial cells can markedly change over time. Discussion VEGF cell signalling regulation in heart repair following myocardial infarction is critical, but the inventor's earlier study demonstrating context dependent SULF1 / SULF2 regulation of this pathway made the inventor question and check out the behaviour of primary coronary artery endothelial cells-the relevant tissue of interest. By modulating HSPG sulfation status, SULF1 and SULF2 have the potential to control the activity of HS-binding growth factors that are expressed in the affected ischemic region during the 1st week [11, 17] that may vary from standard VEGF cell signalling requirements of endothelial cells from other tissues. The inventor's earlier in vitro study of two human endothelial cell lines highlighted differential SULF1 / SULF2 roles in regulating VEGF and TGF0 mediated cell signalling activities. For example, SULF1 over-expression in dermal microvascular HMecl cells, unlike SULF2, promoted both TGF0 and VEGF cell signalling whereas SULF1 over-expression in venous ea926 cells demonstrated the opposite effect as it attenuated both TGF0 and VEGF signalling. SULF2 over-expression in this cell line maintained the control phenotype. The present study demonstrates differences in coronary artery and aortic endothelial cells. The inventor has shown that endothelial cell responses do not only vary in arterial versus venous blood vessels but also vary between endothelial cells located in diverse arterial blood vessel channels in different host tissues. For example, SULF1 in coronary artery endothelial cells inhibited VEGF activity unlike in dermal endothelial cells in which VEGF cell signalling is promoted by SULF1 [7], In addition to SULF1 inhibition, the present study also demonstrates the angiogenic requirement of ANG1 that is one of the other key angiogenic factors in the context of human coronary artery endothelial cell biology in human myocardium [16, 18, 19], The delivery of ANG1 in affected myocardium is also important since ANG1 is also inhibited by SULF1 upregulation induced by hypoxia / ischemia. Unlike ANG1, ANG2 upregulation was apparent in hypoxic coronary artery endothelial cells thus confirming ANG1 and ANG2 playing opposing roles described to regulate microvascular integrity and inflammation following Ml in murine heart [16, 19], ANG2, usually undetectable in resting endothelial cells, is known to be induced in ischemic murine heart triggering hypoxic interference with ANG1-TIE2 cell signalling. The border zone endothelial cells in mice have also been shown to activate ANG2 following Ml that changes the ANG1 to ANG2 ratio promoting vascular leakage and inflammation leading to angiogenic inhibition
[16] , The inventor's in vitro observations of highly dynamic ANG1 / ANG2 ratios in human coronary artery endothelial cell responses support and confirm in vivo observations reported in some rodents
[16] ,
[18] , The TIE2 and VEGF receptor pathways thus appear to work in a complementary and coordinated fashion during myocardial vascular development with VEGF acting during the early stages of vessel development and ANG1 acting later to promote blood vessel maturation, stabilisation and endothelial cell survival. Myocardial infarction induces rapid myocardial apoptosis / necrosis since cardiomyocytes are susceptible to apoptosis during the acute and subacute phases of hypoxia. Timely angiogenic response can reduce Ml-induced damage by mitigating hypoxic injury as the ischemic border zone is considered a unique area that can be rescued by angiogenic therapy. VEGF signalling resulting in the activation of multiple downstream pathways induced by the binding of VEGF ligands to their membrane-bound receptors, however, is regulated at different levels of multiple angiogenic participating constituents representing ligand and receptor expression, the presence of co-receptors and accessory proteins such as angiopoietins, neuropilins, integrins, proteoglycans and Ras / MAPK pathway components to regulate gene expression, cell proliferation and migration. Generation of new blood vessels is maintained by ANG1 cell signalling by activating the TIE2 receptor
[20] , ANG2, an inhibitor of TIE2, signalling further contributes to the regulation of VEGF cell signalling
[18] , Angiogenesis is a complex and dynamic process regulated by both pro- and anti-angiogenic molecules at different stages. SULF1 upregulation in response to hypoxia in coronary artery endothelial cells inhibits ANG1 known to provide vascular protective effects as ANG1 binds and signals through the receptor tyrosine kinase TIE2
[21] , ANG1 is also known to promote endothelial cell migration and inhibit endothelial cell apoptosis and permeability to improve endothelial cell integrity and thus its possible therapeutic use. The critical roles of ANG1 / ANG2 angiogenic regulation are further supported by in vivo studies as both Angl- / - and Tie2- / - mice die quite early during embryonic development showing defective angiogenesis highlighting dilated blood vessels, decreased sprouting, lack of peri-endothelial support and vessel rupture. Ang2 overexpression also produces similar effects to Ang- / - and Tie2- / - null mice implying Angl inhibition coupled with Ang2 promotion in hypoxic coronary artery endothelial cells proves twice as bad during myocardial infarction. Signalling through TIE2 thus appears to depend on the balance between ANG1 and ANG2 and this relationship is broken during hypoxia in coronary artery endothelial cells that is further facilitated through SULF1 / SULF2 activities that differentially change ANG1 and ANG2 levels under hypoxia resulting in vessel destabilisation. Angiogenesis in the border zone surrounding scarred or damaged myocardial region thus would fail due to ischemic up-regulation of deleterious SULF1 and ANG2 and inhibition of protective ANG1 even when VEGF levels are maintained or adequately promoted. Therapeutic angiogenesis in ischemic myocardium would require the inhibition of SULF1 activity, e.g., using neutralising antibodies, and the supply of ANG1 not only to promote VEGF activity but also its subsequent effects to promote blood vessel protective effects in the border zone. Inhibiting SULF1 activity to restore VEGF and ANG1 activities could also inhibit ANG2 upregulation that contributes to blood vessel destabilisation. Further exogenous ANG2 inhibition might also be beneficial. In conclusion, the affected ischemic myocardial region following Ml undergoes remodelling initiated by inflammation to clear the necrotic cardiomyocytes by macrophages and neutrophils before angiogenesis starts in this region. The mismatch between SULF1 / SULF2, VEGF and angiopoietin cell signalling activities upon the onset of ischemia prevents angiogenesis in ischemic myocardium. Thus, without wishing to be bound by theory, the inventor proposes that angiogenesis in partially ischemic myocardium could be re-activated by exogenous SULF1 inhibition that inhibits both VEGF and ANG1, and optionally also SULF2 downregulation to inhibit ANG2 activity, and to reduce fibrosis by TGF0 cell signalling reduction, but still requiring ANG1 provision not indued by hypoxia, thus benefiting from additional exogenous inhibition of ANG2 and enhancement of ANG1, leading to a new treatment of Ml. The foregoing description of the specific embodiments fully reveals the general nature of the invention so that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention. REFERENCES 1. Sayers JR, R. P., Heart regeneration: beyond new muscle and vessels. Cardiovasc Res. 2021, 117, (3), 727-742. 2. Carmeliet P, J. R., Molecular mechanisms and clinical applications of angiogenesis;. Nature 2011, 473 ((7347) ), 298-307. 3. Riching AS, S. K., Cardiac Regeneration: New Insights Into the Frontier of Ischemic Heart Failure Therapy Front Bioeng Biotechnol. 2021, 637538. 4. Oh, G. C.; Choi, Y. J.; Park, B. W.; Ban, K.; Park, H. J., Are There Hopeful Therapeutic Strategies to Regenerate the Infarcted Hearts? Korean Circ J 2023, 53, (6), 367-386. 5. Payne S, G.-R. M., Neal A, Redpath AN, Patel J, Chouliaras KM, Ratnayaka I, Smart N, De Vai S., Regulatory pathways governing murine coronary vessel formation are dysregulated in the injured adult heart. Nature Communications 2019,10(1):3276. 6. Nicolas Ricard, S. B., Christophe Guignabert, Michael Simons Nat Rev Cardiol. 2021, 18, (8), 565-580. 7. Justo T, S. N., Dhoot GK, Context Dependent SULF1 / SULF2 Functional Divergence in Endothelial Cell Activity. Int J Mol Sci 2022, 23, 3769 - 3769. 8. To S. S. T., N. P. M., Hyland V. J., Robinson B. G. and Schrieber L., Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis and Rheumatism 1996, 39, 467-477. 9. Jackson CJ, N. M., Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. IntJ Biochem Cell Biol 1997, 10, 1167-1177. 10. Stewart DJ, K. M., Fitchett D, Freeman M, Camack N, Su Y, Della Siega A, Bilodeau L, Burton JR, Proulx G, Radhakrishnan S, VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Therapy 2009,17, (6), 1109-1115. 11. Justo T, M. A., Dhoot GK, Modulation of cell signalling and sulfation in cardiovascular development and disease. Scientifc Reports 2021,11, 22424. 12. Talman V, R. H., Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res 2016, 365, (3), 563-581. 13. Venugopal H, H. A., Humeres C, Frangogiannis NG, Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction. Cells 2022,11, (9), 1386. 14. Gill, R.; Hitchins, L.; Fletcher, F.; Dhoot, G. K., SULF1A and HGF regulate satellite-cell growth. J Cell Sci 2010,123, (Pt 11), 1873-83. 15. Swerlick RA, L. T., Role of microvascular endothelial cells in inflammation. J Invest Dermatol 1993,100, (1), 111S-115S. 16. Wu X, R. M., Korf-Klingebiel M, Wollert KC, Angiogenesis after acute myocardial infarction. Cardiovasc Res. 2021,117, (5), 1257-1273. 17. Korf-Klingebiel M, R. M., Grote K, Schleiner H, Wang Y, Wu X, Klede S, Mikhed Y, Bauersachs J, Klintschar M, Rudat C, Kispert A, Niessen HW, Lubke T, Dierks T, Wollert KC., Heparan Sulfate-Editing Extracellular Sulfatases Enhance VEGF Bioavailability for Ischemic Heart Repair., Circ Res. 2019,125, (9), 787-801. 18. Sandhu R, T.-K. K., Nag S, Proteau G, Robb MJ, Campbell Al, Kuliszewski MA, Kutryk MJ, Stewart DJ, Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res. 2004, 64, (1), 115-124. 19. Chen JX, S. A., Ang-1 gene therapy inhibits hypoxia-inducible factor-lalpha (HIF-lalpha)-prolyl-4-hydroxylase-2, stabilizes HIF-lalpha expression, and normalizes immature vasculature in db / db mice. Diabetes 2008, 57, (1), 3335-3343. 20. Daseke MJ 2nd, V. F., Kalusche WJ, Ma Y, DeLeon-Pennell KY, Lindsey ML, Neutrophil proteome shifts over the myocardial infarction time continuum Basic Res Cardiol. 2019, 114, (5), 37. 21. Brindle NP, S. P., Alitalo K, Signaling and functions of angiopoietin-1 in vascular protection. Circ Res. 2006, 98, (8), 1014-1023. 22. Gill, R. M.; Michael, A.; Westley, L.; Kocher, H. M.; Murphy, J. I.; Dhoot, G. K., SULF1 / SULF2 splice variants differentially regulate pancreatic tumour growth progression. Exp Cell Res 2014, 324, (2), 157-71. 23. Vichai V, K. K., Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1, (3), 1112-1116. 24. Zaman, G.; Staines, K. A.; Farquharson, C.; Newton, P. T.; Dudhia, J.; Chenu, C.; Pitsillides, A. A.; Dhoot, G. K., Expression of SULF1 and SULF2 in cartilage, bone and endochondral fracture healing. Histochem Cell Biol 2016,145, (1), 67-79. 25. Bellamy WT, R. L., Frutiger Y, Grogan TM, Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59, (3), 728-733. 26. Gill, R. B.; Day, A.; Barstow, A.; Liu, H.; Zaman, G.; Dhoot, G. K., SULF2 gene is alternatively spliced in mammalian developing and tumour tissues with functional implications. Biochem Biophys Res Commun 2011, 414, (3), 468-73. T1. Gill, R. B.; Day, A.; Barstow, A.; Zaman, G.; Chenu, C.; Dhoot, G. K., Mammalian SULF1 RNA alternative splicing and its significance to tumour growth regulation. Tumour Biol 2012, 33, (5), 1669-80.
Claims
1. A combination comprising:an inhibitor of Sulfatase 1 (SULF1),an inhibitor of Angiopoietin-2 (ANG2), andAngiopoietin-1 (ANG1),for use in treating myocardial infarction in a subject.
2. The combination for use according to claim 1, wherein the inhibitor of SULF1 is an anti-SULF1 antibody, for example an anti-human SULF1 antibody.
3. The combination for use according to claim 1 or 2, wherein the inhibitor of ANG2 is an anti-ANG2 antibody, for example an anti-human ANG2 antibody.
4. The combination for use according to any of claims 1-3, wherein the ANG1 is an ANG1 polypeptide, for example human ANG1 polypeptide.
5. The combination for use according to any of claims 1-4, wherein the combination further comprises an inhibitor of Sulfatase 2 (SULF2).
6. The combination for use according to claim 5, wherein the inhibitor of SULF2 is an anti-SULF2 antibody.
7. The combination for use according to any of claims 1-6, wherein the combination furthercomprises an enhancer of ANG1.
8. The combination for use according to any of claims 1-7, wherein the combination is administered to a coronary artery of the subject.
9. The combination for use according to claim 8, wherein the combination is administered to the site of a blockage within the coronary artery of the subject.
10. The combination for use according to claim 8 or 9, wherein the combination is administered upstream of the site of blockage within the coronary artery.
11. The combination for use according to any of claims 1-10, wherein the combination is administered via a bypass, catheter, or a stent.
12. The combination for use according to any of claims 1-11, wherein the combination is administered in the form of a gel.
13. The combination for use according to any of claims 1-12, wherein the combination is administered after the occurrence of the myocardial infarction in the subject.
14. The combination for use according to claim 13, wherein the combination is administered within 3 days of the myocardial infarction.
15. The combination for use according to claim 14, wherein the combination is administered within 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, or 48 hours of the myocardial infarction.
16. The combination for use according to any of claims 1-15, wherein the subject is also administered another treatment of myocardial infarction.
17. The combination for use according to claim 16, wherein the other myocardial infarction treatment comprises administration of an antithrombic agent, such as aspirin.
18. The combination for use according to any of claims 1-17, wherein the combination promotes growth and / or angiogenesis of coronary artery endothelial cells.
19. A pharmaceutical composition comprising an inhibitor of Sulfatase 1 (SULF1), an inhibitor of Angiopoietin-2 (ANG2), and Angiopoietin-1 (ANG1), and a pharmaceutically acceptable carrier, diluent or excipient.
20. The pharmaceutical composition according to claim 19, wherein the inhibitor of SULF1, the inhibitor of ANG2 and the ANG1 are as defined in any of claims 2-4.
21. The pharmaceutical composition according to any of claims 18-20, wherein the composition further comprises an inhibitor of SULF2 as defined in any of claims 5-6.
22. The pharmaceutical composition according to any of claims 18-21, wherein the composition further comprises an enhancer of ANG1.
23. The pharmaceutical composition according to any of claims 18-22 for use as a medicament.
24. Use of a combination as defined in any of claims 1-7 in promoting angiogenesis of coronary artery endothelial cells ex vivo.
Citation Information
Patent Citations
ViewUS2015/030603A1onEspacenetopensinnewtab
ViewUS2011/281803A1onEspacenetopensinnewtab
